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Resumo 
Os tumores de células renais (TCRs) apresentam a taxa de mortalidade mais elevada 
do conjunto das neoplasias urológicas mais comuns. Actualmente, com a crescente utilização 
da imagiologia, a incidência de pequenas massas renais tem vindo a aumentar, o que reflecte 
a necessidade de uma adequada distinção entre TCRs benignos e malignos, uma distinção 
que nem sempre é fácil na prática clínica. De facto e devido ao risco de progressão, em 
situações de dúvida entre TCRs benignos e malignos, a opção terapêutica inclui uma 
abordagem mais invasiva que inclui a nefrectomia, que no caso de alguns TCRs benignos 
seria desnecessária, uma vez que estes pacientes poderiam ser activamente monitorizados. 
Embora a metilação das histonas, mais especificamente as enzimas modificadoras das 
histonas, tenha vindo a ser referenciada como relacionada com a tumorigénese renal, não 
existem até ao momento biomarcadores que auxiliem no diagnóstico e/ou na estratificação 
dos doentes por subgrupos de agressividade tumoral. Assim, o principal objectivo do presente 
trabalho consistiu em determinar quais as metiltransferases (MTHs) e desmetilases (DMHs) 
das histonas relevantes na tumorigénese renal, com especial ênfase nas enzimas capazes de 
distinguir oncocitomas e carcinomas de células renais (CCRs), mais especificamente 
carcinomas cromófobos de células renais (CcCR) bem como demonstrar a sua aplicabilidade 
na monitorização dos doentes com TCRs. Assim, utilizando a tecnologia Taqman® Array 
avaliou-se a expressão de 58 MTHs e 29 DMHs, das quais foram seleccionadas para validação 
três enzimas (que actuam nas lisinas 4 e 36 da histona H3): SMYD2, SETD3 e NO66. Para 
estas três enzimas verificou-se uma sobreexpressão nos TCRs comparativamente aos tecidos 
normais renais (TNRs), tendo-se verificado maiores níveis de expressão em CcCRs e 
oncocitomas comparativamente aos carcinomas de células claras de células renais (CccCRs) 
e carcinomas papilares de células renais (CpCRs). Verificou-se ainda que os níveis de 
expressão da SMYD2 conseguiram discriminar TCRs e TNRs e CcCRs de oncocitomas, 
enquanto os níveis de expressão de NO66 foram capazes de distinguir TCRs benignos de 
TCRs malignos. A análise de sobrevivência demonstrou que a combinação dos níveis de 
expressão de SETD3 e o grau de Führman constituem factores independentes de prognóstico 
para a sobrevida livre de doença, bem como, que a expressão de NO66 consegue predizer a 
sobrevida livre de metástases. Adicionalmente, a expressão proteica de SMYD2 e SETD3, 
avaliada por imunohistoquímica, correlacionou-se com os níveis de transcrito, tendo-se 
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igualmente verificado que o Score A poderá ser útil no diagnóstico diferencial entre TCRs 
malignos e TCRs benignos. Com o objectivo de explorar o papel biológico da SMYD2, o 
biomarcador com melhor desempenho, este gene foi silenciado em duas linhas celulares de 
rim, o que resultou em efeitos fenotípicos divergentes. Assim, na linha 786-O os resultados 
sugerem um potencial papel de supressor tumoral, enquanto que na linha Caki-1, os resultados 
dos ensaios funcionais sugerem um potencial papel oncogénico. Estes resultados podem estar 
relacionados com a diferente origem das linhas em estudo, uma vez que a linha celular 786-O 
é derivada de um tumor primário renal de células claras, enquanto a Caki-1 foi uma linha 
celular estabelecida a partir de uma metástase de carcinoma de células claras. Estes 
resultados parecem sugerir que a função desempenhada pela SMYD2 varia de acordo com o 
contexto celular. Apesar disso, a linha celular Caki-1 parece ser a que melhor mimetiza o 
padrão de expressão observado nos tumores primários. Por último, nas células silenciadas 
para o gene SMYD2, observou-se a desregulação da expressão de genes implicados no ciclo 
celular e apoptose. Concluindo, estes resultados sugerem que as enzimas SMYD2, SETD3 e 
NO66 constituem potenciais biomarcadores em TCRs e que a desregulação da SMYD2 parece 
ser importante na tumorigénese renal, embora estudos adicionais sejam ainda necessários 
para um melhor esclarecimento do seu papel. 
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Abstract 
Renal cell tumors (RCTs) are the most lethal of the common urological cancers. 
Currently, the incidence of renal small masses has been increasing due to widespread use of 
ultrasonography. Moreover, the limitation of this approach in distinguishing benign from 
malignant RCTs represents an important challenge in clinical practice. In fact, owing to the risk 
of tumor progression, in case of doubt between benign and malignant RCT, the option mostly 
includes an invasive approach, which in the case of some benign tumors represent an 
overtreatment as they could be safely monitored by imaging, precluding nephrectomy. Although 
histone methylation, namely the histone modifying enzymes, has been implicated in renal 
tumorigenesis, there are no feasible biomarkers for assisting in diagnosis or for patients’ 
stratification into clinically meaningful subgroups. Hence, the main goal of this study was to 
determine which HMTs and HDMs might be relevant for renal tumorigenesis, focusing on the 
discrimination between oncocytomas and renal cell carcinomas (RCCs), especially 
chromophobe renal cell carcinomas (chRCCs), and to translate those findings for the clinical 
management of RCTs patients. Using Taqman® Array 58 Histone Methyltransferases (HMTs) 
and 29 Histone Demethylases (HDMs) were screened, from which three altered enzymes of 
lysines 4 and 36 of histone H3 were identified: SMYD2, SETD3 and NO66. Specifically, 
SMYD2, SETD3 and NO66 were found overexpressed in RCTs compared to renal normal 
tissues (RNTs) and their expression levels were higher in chRCCs and oncocytomas compared 
to clear cell renal cell carcinoma (ccRCC) and papillary renal cell carcinoma (pRCC). Moreover, 
SMYD2 expression levels discriminated RCTs from RNTs and chRCCs from oncocytomas, 
whereas NO66 expression levels were able to distinguish benign malignant from RCTs. 
Survival analysis revealed that combined SETD3 expression levels and Fuhrman grade were 
independent prognostic factors for disease-free survival, and NO66 expression predicted 
metastasis-free survival. Additionally, SMYD2 and SETD3 protein expression evaluated by 
immunohistochemistry correlated with transcript levels and Score A might assist in differential 
diagnosis between benign and malignant RCTs. Because SMYD2 expression levels were 
found to be a potential biomarker for effective distinction of RCTs from RNTs and, most 
importantly, oncocytomas from chRCCs, we investigated its role in renal tumorigenesis. 
SMYD2 was silenced in RCC cell lines, which resulted in divergent phenotypic effects, 
suggesting a tumor suppressive role in 786-O and an oncogenic function in Caki-1 cells. These 
results might be related with different (primary vs. metastatic) origin of cell lines, although Caki-
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1 seems to better mimic the expression findings in primary tumor tissues. These results suggest 
that SMYD2 function might vary according cellular context. Finally, the expression of several 
genes whose role was relevant in cell cycle control and apoptosis were shown to be 
deregulated in SMYD2-silenced cells. Overall, these results suggest that SMYD2, SETD3 and 
NO66 are putative potential biomarkers for RCTs and that deregulation of SMYD2 is an 
important event in renal tumorigenesis, whose role requires further investigation. 
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1. Kidney Cancer 
The kidney is an essential organ mainly involved in maintaining the body’s homeostatic 
balance and in removing waste products from the blood. It also helps to regulate blood pressure 
and secretes several hormones [1].  
1.1 Epidemiology 
Kidney cancer accounts for nearly 2-3% of all adult malignancies, being the 14th most 
common malignancy. The incidence of kidney cancer varies substantially worldwide, with the 
highest rates being generally registered in Europe and North America and the lowest in Asia 
and South America (Figure 1). According to Globocan, in 2012, there were 337 860 new cases 
and 143 369 deaths attributable to kidney cancer worldwide, for both sexes [2]. Besides, 
approximately 54 000 new diagnoses of kidney cancer are made each year in United States 
and 13 000 patients die of disease [3]. 
 
 
Figure 1 - Age-standardized incidence rates for kidney cancer, for both sexes, worldwide in 2012 [2]. 
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In Europe, kidney cancer is the 8th most prevalent cancer, representing 3.5% of all adult 
malignancies (Figure 2). Indeed, 17.2 new cases and 7.2 deaths per 100 000 habitants in men, 
and 8.1 new cases and 2.8 deaths per 100 000 habitants for women, were reported for kidney 
cancer in 2012 [4]. 
 
Figure 2 - Estimated 5-year prevalent cancer cases for both sexes in 
Europe in 2012. Adapted from [2]. 
 
 In 2012, Portugal registered 612 new cases of kidney cancer in males and 339 in 
females, and 240 deaths in men and 128 in women were accounted to kidney cancer (Figure 
3) [2]. Comparing to other European countries, the incidence of kidney cancer was lower in 
Portugal than in Czech Republic, Lithuania or Germany; however it is observed a 2 fold risk 
ratio increased in men comparing with women [2]. 
 
Figure 3 - Age-standardized incidence and mortality rates for 
kidney cancer by gender in Portugal in 2012 [2]. 
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2. Renal Cell Tumors 
The kidney is composed by a parenchyma, that includes an outer cortex and an inner 
medulla, and by a collecting system, which comprises the renal pelvis and calyces. Kidney 
cancers arising in the renal parenchyma are mainly adenocarcinomas, currently known as 
Renal Cell Carcinomas (RCCs), whereas those that arise from the collecting system are mainly 
transitional cell carcinomas [5]. RCC are the most common renal neoplasia, representing 
approximately 85% to 90% of adult kidney carcinomas [5].  
Among urologic tumors, RCC takes the third place in incidence, following prostate and 
bladder cancer, but it is the most lethal of common urologic cancers, since about 40% of the 
patients with RCC die of this disease, in contrast to the 20% mortality rates associated with 
prostate and bladder carcinomas [6]. 
The causes of Renal Cell Tumors (RCTs) are not fully understood yet, but specific 
lifestyle factors have been recognized as important aetiologic factors for this neoplasia [7].  
2.1. Risk Factors 
2.1.1. Well-Stablished Risk factors 
RCTs are more common in men, with a male to female predominance of 3:2, and occur 
primarily in elderly patients, typically presenting in the sixth and seventh decades of life [6, 7].  
The majority of RCTs are believed to be sporadic, as only 2-4% are due to inherited 
genetic defects, as illustrated by the association of RCTs with family history. Actually, having a 
first–degree relative with RCT is associated with an increased risk of RCC, being reported a 2-
fold increased risk in those situations [8]. There are a few hereditary RCC syndromes 
described. Most of these syndromes present with specific clinical manifestations, which 
involves the formation of renal tumors, mainly frequently multifocal and/or bilateral, and affect 
younger patients than sporadic RCC [7]. Management usually involves early screening, in order 
to allow less invasive therapeutic approaches. The four most common hereditary RCC 
syndromes are the von Hippel-Lindau, hereditary papillary RCC, hereditary leyomiomatosis 
RCC and Birt-Hogg-Dubé [9].  A summary of the hereditary RCC syndromes and related 
affected gene, renal tumors and other clinical manifestations is depicted in Table 1.  
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Table 1 - Hereditary Renal Cell Carcinoma Syndromes. Adapted from [9]. 
Disease Gene Renal Tumors 
Unique Histologic 
Features 
Other Clinical Manifestations 
Von Hippel-Lindau 
VHL, 
3p25-26 
Clear Cell RCC: 
bilateral and multiple 
Classic clear cell RCC 
CNS and retinal 
hemangioblastomas, renal 
cysts, pancreatic cysts and 
neuroendocrine tumors, 
pheochromocytomas, 
endolymphatic sac tumors 
Chromosome 3 
tanslocations 
Unknown; 
VHL? 
Clear cell RCC: 
bilateral and multiple 
Classic clear cell RCC None 
Familial clear cell RCC Unknown 
Clear cell RCC: 
unilateral and solitary 
Classic clear cell RCC None 
Hereditary 
paraganglioma 
SDHB, 
1p36 
RCC with clear and 
eosinophilic cytoplasm 
 
Pheochromocytomas and extra-
adrenal paragangliomas 
Tuberous sclerosis 
TSC1, 
9q34; 
TSC2, 
16p13 
Clear cell RCC 
angiomyolipomas 
Usually clear cell 
RCC, rarely with 
simultaneous 
angiomyolipoma 
Facial angiofibromas, periungual 
fibromas, shagreen patches, 
hypopigmented macules, 
cortical tubers, renal cysts, 
cardiac rhabdomyomas, retinal 
hamartomas 
Hereditary papillary MET, 7q31 
Papillary type 1 RCC: 
bilateral and multiple 
Papillary RCC with 
less frequent 
tubulopapillary and 
cribiform architecture 
“Granular” 
eosinophilic cytoplasm 
None 
Hereditary 
leiomyomatosis RCC 
FH, 1q42-
43 
Papillary type 2 RCC: 
unilateral and solitary 
Very large nuclei with 
prominent 
“melanoma”-like 
nucleoli 
Cutaneous leiomyomas, uterine 
leiomyomas and 
leiomyosarcomas 
Hyperparathyroidism-
jaw tumor 
HRPT2, 
1q25-32 
Papillary RCC, renal 
hamartomas, Wilms’ 
tumor 
Papillary RCC 
Parathyroid tumors, fibro-
osseous mandibular and 
maxillary tumors, renal cysts 
Familial papillary 
thyroid cancer 
?, 1q21 
Papillary RCC, 
oncocytoma 
Papillary RCC Papillary thyroid carcinoma 
Birt-Hodd-Dube 
FLCN, 
17p11.2 
Oncocytic-
chromophobe RCC, 
chromophobe RCC, 
clear cell RCC, 
oncocytomas 
Chromophobe 
histology or with 
oncocytic areas in 
classic clear cell 
carcinoma (hybrid 
tumors) 
Fibrofolliculomas, 
trichodiscomas, acrochordons, 
pneumothorax, colorectal polyps 
VHL: von Hippel Lindau; RCC: Renal Cell Carcinoma; CNS: Central Nervous System; SDHB: succinate dehydrogenase complex, 
subunit B; TSC1: Tuberous Sclerosis 1; MET: MET proto-oncogene; FH: Fumarate Hydratase; HRPT2: cell division cycle 73; 
FLCN: Folliculin 
Cigarette smoking is considered a causal risk factor for RCC by the International 
Agency for Research on Cancer (IARC). In fact, a higher incidence of RCC in smokers has 
been estimated in 2.3 fold risk ratio, directly related to the number of cigarettes, and this effect 
is more evident in men than in women. Evidence on RCC risk reduction due to smoking 
cessation is limited, however it is believed that long-term (10 or more years) smoking cessation 
could alleviate RCC risk [8]. Concerning etiopathogenesis, it is hypothesized that chronic tissue 
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hypoxia resulting from carbon monoxide exposure and smoking-related disorders, such as 
chronic obstructive pulmonary disease, is associated with RCC development [5].  
A high body mass index is associated with an increased risk of RCC development, both 
in men and women, whereas some studies reported a stronger correlation for women. The 
global rise in obesity in the last years support the increased incidence of RCC, and could 
suggest a causal effect [5]. Although the mechanisms by which obesity may cause RCC are 
not well understood, it has been proposed that obesity can induce alterations in renal 
hemodynamics and alter pathways involved in lipid peroxidation, inflammatory response and 
endocrine and metabolic milieu [10]. 
 Hypertension has been associated with RCC risk:  a high systolic (160mmHg) and 
diastolic (100mmHg) blood pressure were reported to double the risk of developing RCC, and 
a dose-response association of increasing RCC risk with rising blood pressure was found [11].  
The effect of antihypertensive drugs independent from hypertension has not been established 
yet, as most studies are based on a diagnosis of hypertension that is inevitably linked to an 
antihypertensive treatment [8]. Even though some studies suggest that these drugs have not a 
causal effect in RCC. Additional studies are warranted to support this hypothesis [8]. The 
biological mechanisms underlying the association between hypertension and RCC are unclear, 
but might include chronic renal hypoxia and lipid peroxidation with formation of reactive oxygen 
species [5]. 
2.1.2. Other risk factors 
Acquired renal cystic disease (ARCD), mostly developed in patients on dialysis, has 
been associated with an increased risk of developing RCC, and approximately 5 to 9% of 
patients with ARCD are thought to will develop RCC.  Cyst epithelial hyperplasia, was proposed 
as the origin of RCC [7].  
A history of diabetes mellitus was also linked to an increased risk of developing RCC, 
despite the fact that an independent role from obesity and hypertension were not conclusively 
demonstrated [5]. 
Although RCC is not a typical occupational disease, some studies reported an 
association between the exposure to some chemicals and an increased RCC risk, namely 
trichloroethylene [8]; organic solvents such pesticides, copper sulphate or benzidine [6]; and 
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heavy metals such cadmium, lead and arsenic [5]. However, study limitations precluded the 
establishment of a causal association between chemical exposure and RCC. 
A diet rich in fruits and vegetables, as well as regular physical exercise, were associated 
with a low risk of RCC [5, 6]. An increased risk of RCC was also reported for women with more 
children [5]. 
2.2. Pathology 
 RCTs are a heterogeneous group of neoplasms, which comprises several different 
histological subtypes, each with a distinct genetic basis and unique clinical features. The 
current (2004) World Health Organization (WHO) renal neoplasms classification combines 
morphological and genetic characteristics, and recognizes four major histological RCTs 
subtypes, three of them malignant: Clear Cell Renal Cell Carcinoma (ccRCC), Papillary Renal 
Cell Carcinoma (pRCC) and Chromophobe Renal Cell Carcinoma (chRCC); and oncocytoma, 
a benign tumor (Figure 4) [12]. Table 2 summarizes the current WHO histological classification 
of RCTs. 
 
Figure 4 – Microscopic representation of the four major histological Renal Cell 
Tumors (RCTs) subtypes: clear cell renal cell carcinoma (ccRCC) [A], papillary 
renal cell carcinoma (pRCC) [B], chromophobe renal cell carcinoma (chRCC) [C] 
and oncocytoma [D]. Original magnification, x200. 
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Table 2 - World Health Organization (WHO) histological classification of RCTs. 
Malignant Neoplasms 
Clear Cell Renal Cell Carcinoma 
Multilocular Clear Cell Renal Cell Carcinoma 
Papillary Renal Cell Carcinoma 
Chromophobe Renal Cell Carcinoma 
Carcinoma of the collecting ducts of Bellini 
Renal Medullary Carcinoma 
Xp11 Translocation Carcinomas 
Carcinomas associated with neuroblastoma 
Mucinous Tubular and Spindle Cell Carcinoma 
Renal Cell Carcinoma, unclassified 
Benign Neoplasms 
Oncocytoma 
Papillary adenoma 
 
 It has been suggested that different histological subtypes may have origin in different 
parts of the nephron: ccRCC and pRCC are believed to be originated from proximal convoluted 
tubule, whereas chRCC and oncocytoma appear to be derived from more distal elements of 
the nephron, such as collecting convoluted tubule (Figure 5) [13]. This common origin could 
explain, according to some authors, similarities in morphological appearance and clinical 
behavior observed between these RCTs subtypes [13, 14]. 
 
Figure 5 - Schematic representation of different RCTs, their presumable 
origin within the nephron and the cytogenetic changes associated to each 
subtype [13]. 
 
Introduction 
 
 
10 
2.2.1. Clear Cell Renal Cell Carcinoma 
Clear Cell Renal Cell Carcinoma (ccRCC) accounts for 70% to 80% of all RCCs, being 
the most frequent RCT subtype. These tumors are typically well-circumscribed and lobulated, 
with a yellow cut surface due to the high lipid content of the tumor cells, and highly vascular, 
and thus hemorrhagic areas can be frequently observed. Areas of necrosis, as well as small 
areas of cystic change, are also apparent [12, 15].  
Microscopically, ccRCC has a varied architecture, with solid, alveolar and acinar 
patterns being the most common. A regular network of small thin-walled blood vessels is 
typical, as well as clear cells due to lipid removal during histological processing.  However, 
some tumors, generally high-grade, may also contain populations of granular, eosinophilic 
cytoplasm, cells. Nuclei appear round and uniform and, depending on tumor grade, the nucleoli 
can be more readily appreciated [12, 15, 16]. Sarcomatoid changes can occur in ccRCC, and 
are associated with a poor prognosis. ccRCCs most commonly metastasize hematogenously, 
via the vena cava, primarily to the lung, although lymphatic dissemination may also occur [12].  
Patients with ccRCC usually have a worse prognosis than patients with pRCC or 
chRCC, even after stratification for stage and grade. 5-year cancer specific survival rate for 
ccRCC is 76,9% [17]. 
Concerning to genetic changes, chromosome 3 alterations and von Hippel-Lindau Tumor 
Suppressor (VHL) mutations are common in ccRCC; indeed, mutation or inactivation of VHL 
gene by hypermethylation was found in the majority (>70%) of ccRCC sporadic cases [12, 16].  
VHL inactivation is thought to be pivotal for ccRCC carcinogenesis. VHL protein targets 
Hypoxia Inducible Factors (HIFs) to ubiquitin-mediated digestion. In the absence of VHL 
protein, due to mutation or promoter hypermethylation of the VHL gene, HIFs accumulate and 
pro-survival and pro-angiogenic factors start to be transcribed, as Vascular Endothelial Growth 
Factors (VEGF) and Platelet-derived Growth Factor (PDGF) [18-20]. 
Because of this frequency, the majority of the studies have been focused in ccRCC, so 
the molecular biology of this tumor is most understand, which led to the development of 
molecular targeted therapies that are used currently [21].   
2.2.2. Papillary Renal Cell Carcinoma 
 Papillary Renal Cell Carcinoma (pRCC), previously known as  chromophilic RCC, is the 
second most frequent renal cancer, representing 10% to 15% of all RCCs. Typically,  it presents 
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as a well-circumscribed mass enclosed within a pseudocapsule. Some tumors may appear 
entirely necrotic and friable, with areas of hemorrhage. pRCC is more likely to be bilateral and 
multifocal than other renal malignancies [12, 15].  
In histology, pRCC is characterized by epithelial cells forming papillae, tubulopapillae 
and tubules in different proportions; aggregates of macrophages, commonly in papillae cores, 
as well as hemosiderin deposits and psammoma bodies, are frequently present [12, 15, 16]. 
Two morphologic variants of pRCC have been described: type 1, accounting for two thirds of 
pRCC, consists of papillae covered by small basophilic, low grade cells, arranged in a single 
layer, and is more frequently multifocal; whereas type 2 includes potentially more aggressive 
variants, with high nuclear grade, cells  presenting abundant eosinophilic and  granular 
cytoplasm, and pseudostratified nuclei. Sarcomatoid differentiation, associated with a poor 
prognosis, may also be seen in pRCC [12, 16]. 
pRCC prognosis is better than ccRCCs in localized tumors, with 5-year cancer specific 
survival rate being 85.1% (in contrast with 76,9% for ccRCC, as previously stated) [17]. 
However, in metastatic tumors, pRCC subtype seems to have a negative impact [17]. 
Moreover, type 2 pRCC were found to have a worse outcome than type 1 pRCC, with a hazard 
ratio of 2.16 [22].  
pRCC characteristic cytogenetic abnormalities include chromosomes 7 and 17 trisomy 
and Y chromosome loss; .other common findings including  chromosome 12, 16 and 20 gain, 
and chromosome 14 loss of heterozygosity [12, 16]. Activating mutations of the c-MET proto-
oncogene, which encodes the receptor for hepatocyte growth factor, has been detected in 
about 10% of sporadic pRCCs [15, 19]. 
2.2.3. Chromophobe Renal Cell Carcinoma 
Chromophobe Renal Cell Carcinoma (chRCC) accounts for approximately 5% to 7% of 
all RCCs and is believed to arise from the intercalated cells of the collecting tubules [12, 13]. 
chRCC is typically a solitary, well-circumscribed, nonencapsulated and solid mass, with 
homogeneous light brown cut surface. Hemorrhage and/or necrosis are rare and, in large 
tumors, a central scar can be seen [12, 16]. 
 Microscopically, the tumor cells are usually arranged in solid sheets. Classic chRCC 
consists of large polygonal cells with finely reticulated cytoplasm, due to numerous cytoplasmic 
microvesicles, and nuclei typically irregular, hyperchromatic and wrinkled, with perinuclear 
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haloes. An eosinophilic chRCC variant can also be found, composed predominantly by cells 
with an intensely eosinophilic cytoplasm [12, 15, 16]. The differential diagnosis between chRCC 
eosinophilic variant and oncocytoma (discussed later) can be challenging. The diffuse 
cytoplasmic staining reaction with Hale’s Colloidal Iron staining observed in chRCC, but not in 
oncocytomas, may be a helpful diagnostic tool [14, 16].  
chRCC prognosis is significantly better than other RCCs as these tumors have a low 
tendency to progress and metastasize: distant (lung, liver, pancreas) metastasis at diagnosis 
were reported for only 1.3% chRCC patients [12], and  the overall 5-year recurrence free 
survival and cancer-specific survival rates were 89,3% and 93%, respectively [23]. 
Genetic analysis has revealed multiple chromosomal losses, the most frequent 
involving the whole chromosomes 1, 2, 6, 10, 13, 17 and 21; flow cytometry analysis has 
demonstrated hypodiploid DNA content in most cases [12, 16]. It was reported an increased 
incidence of TP53 mutations in this histologic subtype [24].  
2.2.4. Oncocytoma 
 3% to 5% of all primary epithelial neoplasms of the adult kidney are renal oncocytomas, 
a benign epithelial neoplasm. It is typically a solitary and well-circumscribed tumor, presenting 
different degrees of encapsulation. The cut surface exhibits a characteristic uniform mahogany-
brown cut surface, with   larger tumors usually presenting a central scarred area [12]. The 
tumors can be fairly large at presentation, however the median size is 4 to 5 cm, and more than 
10% of patients have multifocal or bilateral lesions [12, 16]. 
Microscopically, oncocytoma is characterized by polygonal to round shaped cells, with 
moderate to abundant finely granular eosinophilic cytoplasm, and a small round uniform 
nucleus, called oncocytes. These tumor cells are frequently arranged in solid nests, tubules 
and acini of variable sizes [12, 16].  
Involvement of peripheric fat may be observed in rare cases, although this feature, as 
well as multifocality and bilaterality, does not appear to convey a malignant prognosis in renal 
oncocytoma [16]. 
At the molecular level, most oncocytomas are composed by a mixed population of cells, 
some with normal and others with abnormal karyotypes. Chromosome 1, Y and 14 alterations 
and recurrent chromosomal translocations involving chromosome 11 have been frequently 
found in renal oncocytomas [12]. 
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2.3. Clinical Presentation and Diagnosis 
Because of the retroperitoneal location of the kidney, many renal masses remain 
asymptomatic and nonpalpable until they are in an advanced stage. As the use of imaging 
methods has become more widespread, as part of the diagnostic evaluation of abdominal pain 
or other unrelated diseases, the frequency of incidental detection of RCTs has increased 
significantly, leading to a detection of renal tumors in an earlier stage, in which tumors are 
typically less aggressive and the treatment could be more effective [19]. Although symptoms 
associated with RCTs are becoming less frequent, with the classic triad of flank pain, hematuria 
and palpable abdominal mass being nowadays rarely found [7], they can be due not only to 
tumor growth, but also to hemorrhage (that can obscure the underlying mass), paraneoplastic 
syndromes (found in 20% of RCC patients as fatigue, weight loss and anemia - the most 
frequent - and hypercalcemia, hypertension and polycythemia) or metastatic disease [19]. 
The current approach for renal masses detection and characterization is based in 
imaging techniques as Computed Tomography (CT), Magnetic Resonance Imaging (MRI) or 
Ultrasound (US), with a dedicated renal CT scan remaining the single most important 
radiographic test for delineating the nature of a renal mass, and MRI or US being used when 
CT results are indeterminate or there are contraindications for CT use [19]. Generally, imaging 
can be used to classify renal masses as solid or cystic. In solid renal masses, the most 
important criterion for differentiating malignant lesions is the presence of enhancement, which 
for small renal masses is not always well cleared [7, 19]. For cystic renal masses evaluation, 
Bosniak classification, summarized in Table 3, is recommended.   
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Table 3 - Bosniak Classification. Bosniak classification is based on CT imaging criteria that divides renal cystic 
lesions into 5 categories that are distinct from one another in terms of likehood of malignancy. Adapted from [19]. 
Bosniak 
Classification 
Radiographic Features 
Risk of 
Malignancy 
Management 
I 
Water density 
None 
Surveilance not 
necessary 
Homogeneous, hairline thin wall 
No septa 
No calcification 
No enhancement 
II 
Few hairline thin septa in which “perceived” 
enhancement may be present 
Minimal 
Surveillance not 
necessary 
Fine calcification or short segment of slightly 
thickened calcification in wall or septa 
No unequivocal enhancement 
IIF 
Hyperdense lesion (≤3 cm), well marginated, with 
no unequivocal enhancement 
Minimal 
3%-5% 
Periodic 
surveillance 
Multiple hairline thin septa 
Minimal smooth wall thickening 
“Perceived” enhancement of wall or septae may be 
present 
Calcification may be thick and nodular but must be 
without enhancement 
Generally well marginated 
No unequivocal enhancement 
Hyperdense lesion >3 cm or tatally intrarenal, with 
no enhancement 
5%-10% 
Periodic 
surveillance 
III 
“Indeterminate”, thickened irregular or smooth walls 
or septa in which measurable enhancement is 
present 
50% Surgical excision 
IV 
Clearly malignant lesions that can have all the 
criteria of category III but also contain enhancing 
soft tissue components 
75%-90% Surgical excision 
 
There are, however, some situations in which imaging techniques do not allow a 
conclusive identification of the lesion’s nature. Indeed, there are about 10% to 20% of small, 
solid, CT-enhancing renal masses with features suggestive of RCC that prove to be benign 
after surgical excision of cases [25]. In these cases, biopsy could be an option. Actually, renal 
mass biopsy is being revisited for the evaluation of renal masses, mainly to determine 
malignancy, as well as type and grade of small renal masses, in patients who are potential 
candidates to a wide variety of treatment options, ranging from clinical surveillance to nephron-
sparing surgical excision [26]. Over the years, the false-negative rate of renal mass biopsy was 
thought to be 18%, too high to justify routine use; however, in most of the cases, the renal mass 
could not be adequately evaluated or the material was insufficient for a definitive diagnosis [19]. 
Nowadays, renal mass biopsy is being considered more frequently, since only 10-20% of 
biopsies are inconclusive, overall accuracy in hystotyping is very high (greater than 90%) and 
the risks of clinical complications such as perinephric bleeding and pneumothorax appear to 
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be low [27]. However, it must be considered that benign findings in a biopsy cannot rule out the 
presence of malignancy, mainly when the differential includes chRCC and oncocytoma [26]. 
So, current diagnostic techniques are not feasible enough to reliably distinguish RCC from 
benign renal neoplasms, including oncocytomas. 
2.4. Staging 
 The tumor-node-metastasis (TNM) system is dynamic staging method for stratifying 
patients with cancer, based on data from large multicenter studies with a good level of 
evidence. TNM system characterizes the degree of tumor’s local extension at the primary site 
(T), the involvement of regional lymph nodes (N) and the presence or absence of distant 
metastases (M), and adds numbers to each TNM component to more precisely categorize the 
extent of malignant disease [19]. The American Joint Committee on Cancer (AJCC) proposed 
a revision of the TNM system that is now the recommended staging system for RCC (Table 4). 
For tumors confined to the kidney, size is the only criteria for T stage characterization; 
perinephric tissue invasion, renal vein and vena cava extension and Gerota’s fascia invasion 
are also considered for T stage categorization. Briefly, the most recent changes included a 
subdivision of T2 tumors (T2a are now tumors between 7 and 10 cm and T2b represents tumors 
greater than 10 cm) and the reclassification of tumors with adrenal metastasis, venous thrombi 
and lymphatic involvement, based on prognosis observed in these situations [7, 28]. 
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Table 4 - International TNM Staging System for Renal Cell Carcinoma proposed by the American Joint Committee 
on Cancer in 2009. Adapted from [19]. 
T: Primary Tumor 
Tx Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
T1  Tumor ≤7.0 cm and confined to the kidney 
T1a Tumor ≤4.0 cm and confined to the kidney 
T1b Tumor >4.0 cm and ≤7.0 cm and confined to the kidney 
T2 Tumor >7.0cm and confined to the kidney 
T2a Tumor >7.0 cm and ≤10.0 cm and confined to the kidney 
T2b Tumor >10.0cm and confined to the kidney 
T3 Tumor extends into major veins or perinephric tissues but not into the ipsilateral adrenal 
gland and not beyond the Gerota fascia 
T3a Tumor grossly extends in the vena cava below the diaphragm 
T3c Tumor grossly extends into the vena cava above the diaphragm or invades the wall of the 
vena cava 
T4 Tumor invades beyond the Gerota fascia (including contiguous extension into the 
ipsilateral adrenal gland) 
N: Regional Lymph Nodes 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph nodes metastasis 
N1 Metastasis in regional lymph node(s) 
M: Distant Metastases 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1  Distant metastasis present 
Stage Grouping 
Stage I T1 N0 M0 
Stage 
II 
T2 N0 M0 
Stage 
III 
T1 or T2 N1 M0 
T3 Any N M0 
Stage 
IV 
T4 Any N M0 
Any T Any N M1 
  
2.5. Treatment 
2.5.1. Local Therapy 
 RCT’s management strategies include nephrectomy, thermal ablative therapies or 
active surveillance, depending on tumor size and location, renal function, comorbidities and 
performance status [7]. 
 Notwithstanding advances in the understanding of the genetics and biology of RCC, 
surgery remains the standard for curative treatment. At this time, partial nephrectomy is 
preferred to radical nephrectomy [7, 19, 29]. Whereas radical nephrectomy predisposes to 
chronic kidney disease and subsequent morbid cardiovascular events and increased mortality 
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rates, partial nephrectomy entails complete tumor resection and equivalent oncologic outcomes 
while leaving the largest possible amount of normal functioning renal parenchyma, in order to 
preserve as much renal function as possible [19]. Indeed, partial nephrectomy is the elective 
standard of care for the management of renal small masses, even in the presence of a normal 
contralateral kidney [19]. Radical nephrectomy is performed mainly in patients with locally 
advanced tumor growth, unfavorable location and/or significant deterioration of general health, 
when partial nephrectomy is not suitable [7, 19, 29] 
 Thermal ablative therapies, including renal cryosurgery and radiofrequency ablation, 
emerged as alternative nephron-sparing treatments for patients with localized RCC, and are 
specially recommended in patients with advanced age or significant comorbidities who are not 
optimal candidates for conventional surgery, in patients with local recurrence after previous 
nephron-sparing surgery and in patients with hereditary renal cancer who present with 
multifocal lesions for which multiple partial nephrectomies might be cumbersome. These 
approaches offer the potential for reduced morbidity and faster recovery, but long-term efficacy 
is lower than that reported for traditional surgical approaches due to local recurrence [7, 19, 
29]. 
 Active surveillance might be an alternative for patients presenting small renal masses 
with unapparent local tumor progression and a decreased risk of metastatic disease, specially 
in those who are not candidates for conventional surgery or thermal ablative approaches [19]. 
However, it is necessary to carefully select patients to this approach, as there are tumors with 
high growth rate and that rapidly metastasize, making other treatment options, potentially 
curative, not viable if active surveillance is undertaken [19].  
 
2.5.2. Systemic Therapy 
 For more than 20 years, immunotherapy has been the leading treatment for metastatic 
RCC (mRCC) due to the reports of occasional spontaneous tumor regression and to the 
presence of immune cells in resected tumors, suggesting an important role for the immune 
system in kidney cancer [21]. Interferon Alpha (IFN-α) and Interleukin-2 (IL-2) are the most 
used immune modulators in clinical practice [21], presenting response rates respectively of 5-
15% and 15-20%, but in most cases these responses are partial, specially for IFN-α [30]. High-
dose IL-2 was approved by the U.S. Food and Drug Administration (FDA) for the treatment of 
metastatic kidney cancer in 1992 [21]. Hormonal and chemotherapy are not standard treatment 
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in RCC because response rates of these agents are low. RCC chemotherapy resistance is 
thought to be due to multidrug resistance transporters expression [21]. 
 Recent advances in molecular biology led to the development of novel agents for mRCC 
treatment that block important pathways (angiogenesis, cell cycle regulation) in renal 
carcinogenesis such as VEGF, PDGF and Mammalian Target of Rapamycin (mTOR) pathways 
(Figure 6) [18, 30]. In fact, VEGF and PDGF are upregulated during tumor development due to 
the accumulation of HIFs caused by the inactivation of VHL [18]. VEGF and PDGF antagonists 
include tyrosine kinase inhibitors Sunitinib (the most widely used) and Sorafenib, and a 
monoclonal antibody against VEGF-A, bevacizumab [21, 30]. These agents demonstrated a 
longer progression free survival than IFN-α for Sunitinib (median 11 months versus 5 months) 
[31], and than placebo for Sorafenib (median 5.5 months versus 2.8 months) [32] and 
Bevacizumab (4.8 months versus 2.5 months for placebo) [33]. Axitinib, pazopanib and 
tivozanib, newer agents with selective activity against VEGF family, have recently gained 
attention as possible options fordiminishing  side effects without compromising efficacy [18, 
21].  
mTOR pathway interferes with Phosphatidylinositol 3-Kinase (PI3K) and Protein Kinase 
B (AKT) pathways, as well as Phosphatase and Tensin Homolog (PTEN) suppressor gene,  
potentially involved in HIF’s translation and stability regulation [21, 30]. Temsirolimus and 
everolimus are the most used mTOR inhibitors and they demonstrated a significantly higher 
overall survival when compared with IFN-α (median 10.9 months versus 7.3 months) [34] and 
a superior progression free survival compared with placebo (median 4 months versus 1.9 
months) [31], respectively. Currently, the agents mentioned above, sunitinib, sorafenib, 
bevacizumab, temsirolimus and everolimus, are approved by FDA for mRCC and are used in 
clinical practice [30].  
Current challenges include the development of more selective drugs targeting these 
and others undiscovered pathways important for ccRCC carcinogenesis, that are actually being 
developed, as well as the development of targeted drugs for non-clear cell variants of RCC, 
still not available [18, 21, 30]. 
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Figure 6 - Molecular pathways targeted for therapies in Renal Cell Carcinoma 
[35]. 
2.6. Prognostic factors 
 A gradual improvement in prognosis has been observed for RCTs over time, with 5-
year relative survival rates for RCTs as high as 64% in 2002, compared with less than 40% in 
the early 1960 [36]. Defining RCC prognosis is important for both therapeutic decision and 
patient counseling. Currently, important prognostic factors for cancer-specific survival in 
patients with RCC can be classified as anatomic, histological, clinical and molecular [7].  
 Prognostic anatomic factors comprise, not surprisingly, TNM staging system categories, 
and pathologic stage has proven to be the single most important prognostic factor for RCC [7]. 
As mentioned above, the RCC TNM staging system accurately reflect tumor biology and 
therefore prognosis, so it gives reliable information for distinguishing patients groups with 
different outcomes. Several studies demonstrate 5-year survival rates of 70% to 90% for organ- 
confined disease and document a 15% to 20% reduction in survival associated when perinephic 
or renal sinus fat are invaded, and a significant decrease in survival is observed when tumor 
extends beyond the Gerota fascia to involve continuous organs (including adrenal) or when 
there is lymphatic involvement (5-year survival of 0% to 30%) [19]. Systemic metastases also 
portend a particularly poor prognosis for RCC with a 5-year survival of 0% to 10%, although 
these numbers have improved modestly due to targeted therapies [19]. Tumor size, also a TNM 
category, has proved to have an independent power as a prognostic factor, as small tumors 
have generally a better prognosis, mainly in T3a tumors [37]. 
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 Concerning histological factors, Fuhrman nuclear grade system, consisting of four 
grades based on nuclear size, irregularity and nucleolar prominence has proven in to be an 
independent prognostic. Fuhrman and colleagues reported 5-year survival rates of 64%, 34%, 
31% and 10% for grades 1 to 4, respectively; and nuclear grade proved to be the most 
significant prognostic factor for organ-confined tumors in this series [19]. However, the 
relevance of Fuhrman classification in non-clear cell renal cell carcinomas’ prognosis 
evaluation is not entirely clear, as this grading system was developed for ccRCC [19]. Histologic 
subtype was found to carry prognostic significance too, with some studies, suggesting that 
ccRCCs have a worse prognosis than pRCCs or chRCCs [12, 38], but this prognostic difference 
was lost in multivariable analysis [38]. The presence of sarcomatoid differentiation and necrosis 
has also been described in association with a poor prognosis [7, 19]. 
 Clinical factors as patient performance status, presence of local symptoms, cachexia, 
anaemia and platelet count, have been shown to predict survival, especially in patients with 
metastatic disease. The Eastern Cooperative Oncology Group (ECOG) performance status, 
which uses the ambulatory status to stratify patients, was considered to be an independent 
prognostic factor in a multicenter study [7]. 
 Several molecular markers appear to be independent prognostic factors for RCC, as 
Carbonic Anhydrase IX (CA-9), reported as an independent prognostic biomarker associated 
with poorer survival in patients with metastatic disease [39]. Additionally, CD274 molecule (B7-
H1), which is a T-cell coregulatory molecule, demonstrated to be associated with metastatic 
cancer progression and death from RCC, even after adjusting for pathological and clinical 
variables [40, 41]. Marker of proliferation Ki-67 (Ki-67), correlated with reduced survival [41, 
42]; Tumor Protein p53 (TP53) overexpression associated with disease progression in ccRCC 
[39, 43]; and vimentin, that also showed statistical power in predicting survival [39]. The 
incorporation of molecular biomarkers into panels can improve their applicability; indeed, a 
molecular signature of five molecular biomarkers including Ki-67, TP53, endothelial fms-related 
tyrosine kinase 1 (VEGFR-1), epithelial VEGFR-1 and epithelial c-fos induced growth factor 
(VEGF-D) was found to predict disease free survival for localized ccRCC with an accuracy of 
0.838 [44], and a panel including B7-H1, survinin and Ki-67 was reported to enhance the 
prognostic ability of each of the individual prognostic features [41]. Although the promise of 
incorporating molecular biomarkers in clinical practice, several limitations, as the methods used 
in assigning predictive values, must be noted.  
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 Currently, some normograms combining various prognostic factors have been 
developed, and it is believed that they will improve the ability to stratify patients with RCC and 
help to guide counseling and follow-up of RCC patients by identifying patients more likely to 
benefit from specific interventions [39, 41].  
2.7. The problem of distinguishing Chromophobe Renal Cell Carcinomas 
and Oncocytomas 
 One of the most common diagnostic problems in urologic pathology remains the 
differential diagnosis of renal oncocytoma and chRCC, specifically the eosinophilic variant of 
chRCC [16, 45]. The distinction between those neoplasms is important because oncocytomas 
are benign and chRCCs are low-grade malignant neoplasms that sometimes behave 
aggressively and carry a risk of recurrence and distant metastases [14]. Their possible common 
origin in the intercalated cells of collecting tubules of the nephron is suggested to explain the 
overlapping features observed [13, 14, 45]. 
 Currently, the detection of renal tumors is frequently made by radiological imaging using 
ultrasonography, CT or MRI [16]. This has led to a diagnostic dilemma of accurately 
characterizing the nature of these renal lesions and their subsequent management. The theory 
states that RCCs on CT scans are solid heterogeneous masses with contrast enhancement, 
and that chRCC usually demonstrates homogeneous enhancement and calcification, whereas 
oncocytomas typically show as a well-defined and relatively homogeneous solid mass. These 
characteristics are not consistently reliable, and pathognomonic CT scan features that can 
safely differentiate oncocytomas from chRCCs are lacking [19]. Even on multiphasic 
multidetector CT scan [46] and MRI [47] studies, oncocytomas and chRCCs exhibited similar 
findings, which may not allow a feasible differentiation between them. Although some results 
seem to be promising, as arterial enhancements >500% and washouts values >50% being only 
observed in oncocytomas in multiphasic CT scans [48], there are until now no consensual 
characteristics that enable a proper distinction between oncocytomas and chRCCs, and 
therefore most oncocytomas are treated as RCCs based on imaging.  
 chRCC and oncocytomas also share some macroscopic and microscopic 
characteristics, as previously described. Both are typically well circumscribed, solid and 
homogeneous tumors, oncocytomas being mahogany-brown coloured, one-third presenting  a 
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central scar, and not capsulated, whereas chRCC are  tan to brown coloured, less commonly 
present a central scar and usually are capsulated [16, 45]. Indeed, it was described that the 
presence and thickness of a fibrous capsule could distinguish chRCCs from oncocytomas with 
statistical power (it is significantly more common and thicker in malignant tumors compared 
with oncocytomas) [49]. Histologically, the eosinophilic cell cytoplasm is the major cause of the 
problems in distinguishing oncocytomas from chRCCs, specially in small biopsies; however the 
presence of perinuclear halos, irregular nuclei with well-preserved chromatin and binucleation 
are characteristic of chRCCs and can help in this differential, by ruling out oncocytomas [16, 
45].  
 Some ancillary techniques could help to differentiate chRCCs from oncocytomas, as 
Halle’s colloidal iron, typically with a strong and diffuse staining pattern in chRCCs and a focal 
and weak staining pattern in oncocytomas [16]. However, there are some cases that do not 
show this staining pattern, making histochemical staining a limitative technique when 
considered alone. At the immunohistochemical level, there is a significative overlap between 
these two tumors: they are both negative for vimentin, CA-9 and racemase and positive for v-
kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (CD117) and cadherin and 
show variable staining results for CD10 and epithelial membrane antigen [14, 45]. Cytokeratin 
7 staining pattern is different between chRCC and oncocytomas, strong and diffuse in chRCC 
and weaker and multifocal in oncocytoma, but this is of limited use especially in small biopsies 
[14, 45]. 
Several studies tried to identify biomarkers that could differentiate oncocytomas from 
chRCCs, as Caveolin-1, positive in 87% of chRCC and negative in oncocytomas and MOC-31, 
positive in 96% of chRCC and 25% of oncocytomas [50]; Wingless-type MMTV integration site 
family, member 5A (Wnt-5a), expressed in all oncocytomas but only in 18% of chRCCs [51]; 
protein S100A1, positive in oncocytomas and mostly negative in the chRCC eosinophilic variant 
[52] and EBNA3A nuclear protein (LMP2), with a strong nuclear expression in chRCCs 
eosinophilic variant and only in few (4%)oncocytomas, the  sensitivity and specificity in 
distinguishing chRCC from oncocytoma being 100% and 98%, respectively [53]. A panel of 
three biomarkers including S100A1, CK7 and Claudin 8 was also proposed to distinguish 
between chRCC and oncocytoma [54], as well as a panel of five genes responsible for encoding 
tight junction proteins and vesicularmembrane trafficking proteins, retained in chRCCs and lost 
or consistently downregulated in oncocytomas, one of them, Mal, T-cell differentiation protein 
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2 (MAL2), also presenting this differential expression at protein level, by immunohistochemistry 
[55]. 
Although several studies reported numerous promising biomarkers in distinguishing 
oncocytomas from chRCCs, there are also some inconsistent results between them, mainly 
due to the few number of cases studied [14, 45]. Until new specific molecular biomarkers that 
allow an accurate diagnosis of these tumors via non-invasive strategies are discovered, all 
suspicious renal masses will continue to be surgically excised, since the differentiation of these 
two entities by imagiology is unreliable, despite that some of them could have been 
conservatively management if they were properly identified [14].   
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3. Epigenetics 
3.1. An Emerging Field 
 Epigenetics was firstly introduced in 1939 by Waddington, who defined it as “the causal 
interactions between genes and their products, which bring the phenotype into being”; currently 
epigenetics refers to heritable changes in gene expressions that are not due to any alteration 
in the DNA sequence [56].  
 It is now acknowledged that epigenetics are implicated in a wide variety of biological 
processes, not only during embryonic development but also during differentiation. In fact, 
epigenetics is required, for instance, to genomic imprinting at one of the two parental alleles of 
a gene in order to stablish monoallelic expression as well as for X-chromosome inactivation in 
females [57, 58]. Given that, a disruption in the normal balance of epigenetic marks can result 
in a deregulation of various signaling pathways, and consequently can lead to disease states 
such as cancer [59]. 
Currently, three main epigenetic mechanism are recognized: DNA methylation, post-
translational modifications of histone proteins and chromatin remodeling and non-coding RNAs. 
These three mechanisms are dynamic and they work together in order to regulate gene 
expression. Additionally, they also interact with each other [60]. 
3.1.1. DNA Methylation  
 DNA methylation is the most extensively studied epigenetic modification in mammals. 
It consists in the addition of a methyl group at the 5’ position of a cytosine ring within CpG 
dinucleotides, mainly found in CpG islands [61]. CpG islands are characterized by a CG content 
of 50% at least and a ratio of observed/expected CpG dinucleotides of at least 0.6 [60]. 
Moreover, CpG islands exists in about 60% of human gene promoters, which makes DNA 
methylation an important regulatory mechanism of gene transcription [58, 62]. This alteration 
is catalyzed by enzyme DNA methyltransferases (DNMTs), which catalyze the transfer of a 
methyl group from S-adenosyl methionine to DNA. In mammals it has been reported five 
members of DNMTs, although only DNMT1, DMNT3a and DNMT3b possess methyltransferase 
activity [58, 60, 61]. DNMT1, the maintenance DNMT, operates in hemimethylated DNA, being 
responsible for maintaining the existing methylation patterns following DNA replication. It is the 
most abundant DNMT and it also has de novo DNMT activity.DNMT3A and DNMT3B are de 
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novo enzymes that target unmethylated CpGs to initiate methylation [60]. Among DNMTs 
without methyltransferase activity, DNMT-3L is important for establishing maternal genomic 
imprinting, also acting as a general stimulatory factor for DNMT3a and DNMT3b [60, 63]. 
 In normal cells, DNA methylation plays an important role in maintenance of genomic 
imprinting, transcriptional regulation, developmental processes and genome integrity. In fact, 
this alteration occurs predominantly in repetitive genomic regions to maintain genomic 
integrity[58]. Concerning gene expression, CpG islands DNA methylation is generally 
associated with gene repression and with chromatin repressive states. This transcription 
inhibition occurs directly by blocking the binding of specific transcription factors and indirectly 
by recruitment of methyl-CpG-binding domain (MBD) proteins, which in turn recruit histone 
modifying and chromatin-remodeling complexes to methylated sites which ultimately mediate 
gene repression [58, 60]. 
3.1.2. Histone Post-Translational Modifications and Chromatin Remodeling 
The nucleosome is the basic unit of chromatin and it is composed of an octamer of 
histone proteins around which 146bp of DNA are wrapped. Histone are small basic proteins 
containing a globular domain, which directly interacts with DNA, and a flexible charged N 
terminal, also known as the histone tail, which protrudes from the nucleosome and can be 
altered by different post-translational modifications, such as methylation or acetylation [58]. The 
octamer that compose nucleosome consists of two subunits of each of the following core 
histone proteins: H2A, H2B, H3 and H4 [61].  
Chromatin structure is controlled by two main classes of protein complexes: those that 
remodel nucleosomes in an ATP-dependent manner and those that covalently modify histone 
tails and involve the recruitment of chromatin modulators [64]. Both determine chromatin status, 
which can be a more condensed pattern, called heterochromatin, or a more uncondensed 
configuration, euchromatin. In fact, herochromatin has a highly package conformation 
comprising mostly inactive genes, whilst euchromatin is relatively uncondensed and represents 
loci being actively transcribed [61].  
Chromatin remodeling complexes are multisubunit complexes that use ATP hydrolysis  
to alter the interaction of DNA and nucleosome and therefore alter the conformation of 
chromatin. ATP-dependent chromatin remodelers can be further divided into families on the 
basis of subunit composition and biochemical activity, and these families include SWI/SNF, 
SWR1, chromatin helicase DNA-binding proteins (CHDs), ISWI and INO80 [65]. The SWI/SNF 
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complex is the best studied and it consists of 9 to 12 subunits [66]. In mammals, these 
complexes are comprised of one of two mutually exclusive catalytic ATPase subunits, brahma 
homologue (BRM) or BRM/SWI2-related gene 1 (BRG1), a set of highly conserved core 
subunits, SNF5, BAF155 and BAF170, and variant subunits that are thought to contribute to 
the regulate the specific function of the complexes [65, 66]. They are reported to remodel 
nucleosome structure by repositioning DNA in relation to the nucleosome or by catalyzing the 
ejection or insertion of histone octamers [66]. 
The modulation of chromatin conformation though covalent post-translational 
modifications (PTMs) of histones is another fundamental mechanism of gene transcription 
regulation. Currently, it is described several PTMs, including methylation, acetylation, 
phosphorylation, ubiquitylation, sumoylation, ADP ribosylation, deamination among others less 
studied [67]. Histone modifications are thought to alter the electrostatic charge of the histones, 
resulting in a changing in their binding of DNA, which in turn results in different status of 
euchromatin or heterochromatin and consequently in altered transcriptionally activity. The most 
studied and well characterized are histone acetylation and methylation, which are established 
by several enzymes with variable residue-specificity. Generally, histone acetylation occurs at 
lysine residues and is associated with a more open chromatin conformation, by neutralizing 
positive charge of lysine residues that facilitates access to transcriptional machinery and 
thereby leads to gene activation [67]. The enzymes that catalyze this modification are histone 
acetyltransferases (HATs) and those that remove the acetyl groups are histone deacetylases 
(HDACs). Concerning histone methylation, it is more complicated to understand its 
consequences for DNA transcription as unlike acetylation, methylation does not alter the 
charge of the residues, so the transcriptional effects depends on the residue affected as well 
as the degree of methylation (mono, di or trimethylation) [67]. Histone methylation is stablished 
by histone methyltransferases (HMTs), which are responsible for adding methyl groups to 
histone tails, and histone demethylases (HDMs), characterized by its removing [68]. Histone 
modification levels are predictive of gene expression and recent studies have shown that 
generally, actively transcribed genes are characterized by high levels of trimethylation of lysine 
4 of histone H3 (H3K4me3) and acetylation of lysine 27 of histone H3 (H3K27Ac) [58, 60]. 
As mentioned above, histone modifications can be regulated by histone modifying 
enzymes, which transfer and revert chemical modifications, such as HATs and HMTs (writers) 
and HDACs and HDMs (erasers), respectively, or mediate between modification and proteins, 
translating the histone code (readers) (Figure 7) [68]. 
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Figure 7 - Histone modifying enzymes and their role in controlling histone modifications and 
consequently gene expression [68]. 
 
3.1.3. Non-coding RNAs 
Non-coding RNAs are a class of RNAs that do not encode for proteins, although they 
are biological functional, being relevant to a correct development and to control several 
molecular pathways [69]. In fact, they have been implicated in different molecular events in 
eukaryotic cells, including chromosome dynamics, splicing, RNA editing, inhibition of 
translation and mRNA destruction. Non-coding RNAs comprise several different classes, 
according to their length and their function [69]. Among the different classes described until 
now, microRNAs (miRNAs) are the most widely studied.  
miRNAs are a class of endogenous single-stranded non-coding RNAs, with 18 to 25 
nucleotides in length, which are synthesized and processed in the nucleus and then exported 
to the cytoplasm [70]. Their effect on mRNAs regulation depends on the level of 
complementarity between miRNA and its target mRNA sequence as a total complementarity 
conducts to site-specific cleavage, whereas imperfect match leads to mRNA degradation. 
Initially, miRNA have been reported as negative regulators of mRNA expression, however 
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recent data have indicate an opposite effect, partly explained by binding sites of miRNAs in 
target mRNA. 
Each miRNA may regulate multiple mRNAs and, conversely, each mRNA may be 
targeted by multiple miRNAs. In fact, it is estimated that 30 to 70% of human genes are 
regulated by miRNAs, in a temporal and tissue specific manner. Hence, altered miRNAs can 
dramatically affect a variety of cellular processes, namely proliferation, cell death, differentiation 
and development. 
3.2. Epigenetics in Cancer 
Nowadays, genetic mechanisms are not the only path to gene disruption in cancer. 
Indeed epigenetic alterations are increasingly emerging as another crucial pathway of tumor 
development by altering gene expression. In fact, the epigenome has been implicated in 
various phases of neoplastic development, which include tumor initiation, invasion and 
metastasis and currently several epigenetic biomarkers for diagnosis and prognosis have been 
well stablished in some cancer models [63]. Besides epigenetics are also implicated in 
predicting response to specific treatments, such as O-6-methylguanine-DNA methyltransferase 
(MGMT) promoter methylation is described to predict the response of glioblastomas to 
alkylating drugs. Given that, epigenetics are an important field in Oncology, and hence cancer 
epigenome is characterized by global changes in epigenetic mechanisms [63]. 
Alterations on DNA methylation pattern have been widely described in cancer. In fact, 
there some cancer models, in which the second hit that leads to gene inactivation and therefore 
to tumor initiation is hypermethylation. It is the case of E-cadherin (CDH1) in gastric cancer or 
VHL in ccRCC. Tumor cells are characterized by DNA methylation global loss, particularly in 
repetitive DNA sequences, which is related with malignant phenotypes by promoting 
chromosomal instability, reactivation of transposable elements and loss of imprinting. Beyond 
global hypomethylation, it is also observed hypermethylation at specific CpG islands, mainly in 
promoter regions of tumor suppressor genes, which results in its inhibition and consequently 
tumor development [56]. 
Concerning histone post-translational modifications and chromatin remodeling, they are 
key mechanisms in gene regulation, and consequently they also have been found deregulated 
in cancer [60]. The most proeminent alteration in histone modification in cancer cells is a global 
reduction of monoacetylated lysine 16 of histone H4 (H4K16Ac) [58] as well as a global loss of 
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active mark H3K4me3 and a repressive mark of trimethylation of lysine 20 of histone H4 
(H4K20me3), and a gain in the repressive marks of methylation of lysine 9 of histone H3 
(H3K9me) and trimethylation of lysine 27 of histone H3 (H3K27me3) [60]. These alterations 
are stablished by histone modifying enzymes, whose expression have also been reported as 
deregulated in some cancer models. Hence, abnormal patterns of histone modifications due to 
altered expression and/or activity of key chromatin modifying enzymes were implicated in 
tumorigenesis [71]. Besides, it is reported a direct interplay between DNA methylation and 
histone modifications, with hypermethylation of CpG islands in the promoter regions of tumor 
suppressor genes in cancer cells is associated with particular combinations of histone marks, 
such as deacetylation of histone H3 and H4, loss of H3K4me3 and gain of H3K9me and 
H3K27me3 [72]. 
Concerning chromatin remodeling, SWI/SNF complexes have been described to 
directly linked to cancer development, as specific inactivating mutations in some subunits of 
this complex have been found in various human cancer [73]. In fact, mutations subunits of the 
complex (such as BRG1 and SNF5) cause chromatin deregulation, which stringly influence 
tumor progression [66]. The disruption of chromatin remodeling may result in an altered 
chromatin structure that affects gene expression and perturbs the normal signaling pathways 
[65].  
 miRNAs are currently considered an emerging field in oncology, with several studies 
reporting an altered pattern expression pattern in several cancer models. They can act either 
as oncogenes, when they exert their repression activity in tumor suppressor genes (called 
oncomiRs) or tumor suppressors, if they inhibit oncogenes, which highlights that the role of 
miRNAs in cancer depends upon their specific target genes [74]. Globally, miRNAs are 
downregulated in cancer, even though specific upregulation has also been described [61]. The 
mechanisms by which miRNAs can be deregulated include gene amplification, deletion, 
mutation, chromosomal abnormalities and also epigenetic mechanisms. Indeed, DNA 
methylation can modulate the expression of miRNAs, and currently there are several miRNAs 
reported to be silenced by hypermethylation of its promoter [63].  
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4. Histone Methylation and Renal Cell Tumors 
4.1. Histone Methylation  
As with other PTMs, histone methylation is dynamic. Histone methylation can occur in 
the side chains of lysines, by lysine histone methyltranferases (KMTs) or in arginines residues, 
by protein arginine methyltransferases (PRMTs). Lysine may be mono, di or tri-methylated, 
whereas arginines can only be targeted for mono or di-methylation (symmetrically or 
asymmetrically). The reversibility of histone methylation has been stablished thought the 
discovery of histone lysine and arginine demethylases [67].  
As mentioned above and unlike acetylation, methylation does not change the charged 
state of lysines or arginines, so there is not a global gene expression result, like a gene 
activation in histone acetylation, but instead an effect that is dependent of the residue 
methylated as well as the degree of methylation observed (Figure 8) [68]. The impact of methyl 
marks on gene expression depends on other proteins, which can bind to these specific sites or 
simply regulate chromatin sites. Histone lysine methylation can be associated with either 
transcriptional activation or repression. In fact, H3K4me3 and dimethylation of lysine 4 of 
histone H3 (H3K4me2) are highly enriched at transcriptionally active gene promoters, whereas 
H3K27me3 and trimethylation of lysine 9 of histone H3 (H3K9me3) are present in 
transcriptionally repressed promoters [58]. Concerning histone arginine methylation and 
although much less is known about its effects on nucleosome dynamics, it has been further 
studied in recent years and currently it is recognized as an important transcriptional regulatory 
mechanism that promote or antagonize the interaction of nuclear factors [68]. 
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Figure 8 - Major lysine methylation marks on histones H3 and H4. The effect 
on gene expression is dependent of the residue methylated and the degree 
of methylation observed [75]. 
 
Until now, more than 50 HMTs and HDMs were identified (Figure 9) [76]. All HMTs use 
S-adenosylmethionine (SAM) as a co-substracte to transfer methyl groups and some of them 
have been reported to can methylate not only histone but also non-histone proteins [68]. With 
the exception of Dot1 methyltransferase, all KMTs contain a SET domain that harbours the 
enzymatic activity [67]. PRMTs can be classified by its type of methylation: type I enzymes 
leads to symmetric arginine methylation while type II is responsible for the asymmetric process 
[67]. Concerning HDMs, they are categorized in two different groups: Lys-specific 
demethylases (LSD) and Jumonji C (JMJC) histone demethylases. The JMJC family 
demethylates mono, di, and tri-methylates lysines enzymes, whereas LSD family proved to be 
unable to catalyze the demethylation of the trimethylated state [67, 75].  
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Figure 9 - Phylogenetic trees of epigenetic protein families: protein methyltransferases 
(PMTs) and lysine demethylases (KDMs). Adapted from [68] 
 
 Recent studies have suggested that HMTs and HDMs deregulation might be crucial to 
cancer onset and progression. In fact, the alteration of these enzymes, reported as due to gene 
mutations or altered gene patterns, are emerging as an important group of molecules which 
can serve as biomarkers, not only in diagnosis but also with a prognostic purpose [68].  
4.2. Post-translational histone modifications in Renal Cell Tumors (RCTs) 
As previously mentioned, hypoxia is implicated in renal tumorigenesis, especially 
ccRCC [77]. Recently, evidence of a robust link between hypoxia and post-translational histone 
modifications has been provided. Indeed, hypoxia induces a pool of alterations in histone 
marks, globally associated with repression but also with activation of genes, although the 
transcriptional effect is mostly gene-specific, affecting hypoxia-activated or -repressed genes 
[78]. In human embryonic renal cell line HEK293, hypoxia increases global di-methylation levels 
of lysine 9 of histone H3 (H3K9me2), being responsible for augmented methyltransferase G9a 
activity, leading to gene repression [79]. 
In RCTs histone modifications seem to play an important role in cancer progression and 
may, thus, serve as prognostic biomarkers. In this vein, it was demonstrated that global levels 
of acetylation of histone H3 (H3Ac) and histone 4 (H4Ac) as well as of lysines 9 and 18 of 
histone 3 (H3K9Ac and H3K18Ac, respectively) were similar among different RCT histological 
subtypes, although a trend for lower expression in RCC compared to oncocytomas was 
depicted [80]. In this study, interesting associations between histone deacetylation and 
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prognosis were depicted. Indeed, H4Ac levels were inversely correlated with pathological stage 
and nuclear grade, whereas lower H3Ac levels associated with systemic metastatic spread and 
tumor progression [80]. Furthermore, low H3K18Ac levels significantly correlated with RCC 
progression in univariate analysis and it independently predicted cancer progression following 
surgery, in localized RCC [80]. These findings corroborate and extend those of a previous 
study, which demonstrated that low H3K18Ac levels associated with poorer survival [81]. 
Remarkably, these histone modification patterns were shown to be independent 
prognosticators of localized RCC, independently of grade, proliferation rate and p53 expression 
[81]. 
Concerning histone methylation, a study analyzed the global methylation pattern of 
lysine 4 of histone H3 (H3K4) in a series of 193 RCCs and 10 oncocytomas [82]. It was shown 
that different H3K4me2 and H3K4me3 expression levels were significantly higher in 
oncocytomas compared to RCC [82]. However, lower H3K4 methylation (mono-, di- and tri-
methylation) expression levels were associated with adverse clinico-pathological parameters 
such as more advanced pathological stage and higher Fuhrman grade, as well as with distant 
metastasis and lymphatic invasion, although the former only associated with H3K4me2 
expression levels [82]. Although, in univariate analysis, low levels of all states of H3K4 
methylation were predictive of progression-free and cancer-specific survival, in a multivariate 
analysis no statistical significance was depicted [82]. However, an H3K4me score, empirically 
established by the authors, was an independent predictor of progression-free survival in 
patients with RCC, independently of pathological stage and Furhman grade [82]. Similar results 
have been reported in a different study, in which lower expression of H3K4me2 was significantly 
associated with decreased disease survival [80]. It was also reported that methylation H3K9 
was of prognostic significance in RCC patients [81]. Indeed, in multivariate analysis which 
included grade, tumor location and the immunoexpression of other biomarkers of putative 
relevance in RCC (Ki67 index and p53), H3K9me2 levels were shown to be significant 
predictors of disease outcome [81]. Finally, mono- and di-methylation expression levels of 
lysine 27 of histone H3 (H3K27me1 and H3K27me2, respectively) were shown to be 
significantly higher in pRCC compared to other RCC subtypes, whereas H3K27me3 were 
significantly higher in oncocytomas than in RCC, regardless of subtype [83]. Furthermore, lower 
H3K27me1, H3K27me2 and H3K27me3 expression levels associated with advanced 
pathological stage, higher Fuhrman grade, and vascular invasion, and lower H3K27me3 
expression levels were observed in patients with distant metastasis [83]. Additionally, 
progression free-survival was shorter in patients with lower H3K27me1 and H3K27me3 
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expression levels, although in a univariate analysis only; instead a H3K27 score, combining 
immunoexpression level of each methylation state, was a significant and independent predictor 
of RCC progression-free survival [83]. 
Globally, the aforementioned studies highlight the prognostic relevance of histone post-
translational modifications in RCTs. Importantly, specific patterns of those alterations added 
non-redundant prognostic information, augmenting the accuracy of prediction of clinical 
behavior in RCT patients. Eventually, this information might aid clinicians to identify patients 
that might benefit from emerging adjuvant therapies and/or represent novel therapeutic targets 
for patients with RCTs. 
4.3. The emerging role of chromatin modifiers in renal cell tumorigenesis 
Recent results from genomewide sequencing projects in RCTs have identified recurrent 
mutations in chromatin remodeling components, which have an important impact in tumor 
initiation and/or progression. The relevance of Polybromo 1 (PBRM1) gene, encoding for 
BAF180 protein (a subunit of the PBAF SWI/SNF chromatin-remodeling complex) in ccRCC, 
has been recently acknowledged [84]. Genetic sequencing of 227 primary ccRCC revealed that 
truncating mutations in PBRM1 were present in 41% of cases, making it the second most 
commonly altered gene in ccRCC, following VHL [84]. Phenotypic in vitro assays (evaluating 
cell proliferation, colony formation and cell migration) supported a tumor suppressive role for 
PBRM1 in ccRCC, involved in the control of cellular proliferation and chromosomal stability  
[84]. Importantly, PBRM1 mutation occurred at similar rates in tumors with or without VHL 
mutations, and no significant correlation was depicted between lack of PBRM1 expression and 
VHL mutations, indicating a major role for PBRM1 mutations in the genesis of ccRCC [85]. 
ARID1, which encodes for the BAF250A subunit of the SWI/SNF complex, was also found to 
be mutated in RCCs, although in a very small proportion of cases, which also harbor PBRM1 
mutations [84]. Furthermore, decreased ARID1 expression was reported in approximately 30% 
of primary RCC cases [86]. 
Mutations in other genes encoding for enzymes which carry out histone post-
translational modifications have also been reported in ccRCC, including SETD2 (H3K36 
methyltransferase), JARID1C/KDM5C (H3K4 demethylase), UTX/KDM6A (H3K27 
demethylase) and MLL2 (H2K4 methyltransferase) [77, 87-90]. These mutations, however, 
occur in a smaller proportion of cases, representing altogether approximately 15% of all 
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mutations reported in ccRCC. These are mainly inactivating mutations, which are not mutually 
exclusive, since SETD2 and JARID1C/KDM5C mutations occur in tumors which harboring VHL 
mutations and/or the hypoxia-related phenotype [87]. SETD2 was proposed as a novel tumor 
suppressor gene in ccRCC, and its mutations associate with loss or decrease of tri-methylation 
of lysine 36 of histone H3 (H3K36me3) [91]. Interestingly, a similar role was also suggested for 
UTX/KDM6A, as its deregulation causes altered expression of genes encoding for 
metallothioneins [87, 92]. Furthermore, an important role for JARID1C/KDM5C in renal 
carcinogenesis was also reported as VHL inactivation decreases H3K4me3 through HIF-
mediated increase in JARID1C, which in turn suppresses HIF-responsive genes and, 
consequently, tumor growth [93]. This tumor suppressive effective of JARID1C/KDM5C may 
be, however, compromised by mutations, which thus promote ccRCC progression [93]. 
The BRCA1 Associated Protein-1 (BAP1) gene, encoding a nuclear deubiquitinase 
targeting H2A, is also mutated in 8-14% of ccRCC cases [77, 89, 94]. It interacts with Host Cell 
Factor C1 (HCF-1), which serves as a scaffold for several chromatin-remodeling complexes 
and also recruits histone-modifying enzymes, and this interaction promotes the inhibition of cell 
proliferation [94]. Remarkably, BAP1 mutations are mutually exclusive with PBRM1 mutations 
and loss of BAP1 or PBRM1 gene products has been observed in approximately 70% of ccRCC 
cases, highlighting the importance of these two genes in the genesis of ccRCC [89, 94]. 
Gene expression analyses also identified histone modifiers differentially expressed in 
RCTs. Overexpression of UTX/KDM6A and JMJD3 (H3K27 demethylases) and EZH2 (H3K27 
methyltransferase) in ccRCC compared to adjacent normal tissues has been reported [95] and 
EZH2 was shown to stimulate RCC proliferation through targeting of cyclin-dependent kinase 
inhibitor 1B (p27) [96]. Indeed, p27 expression is increased when EZH2 depletion occurs, 
suggesting a potential oncogenic role for EZH2 in RCC [96]. Concerning HDACs, HDAC 1 and 
HDAC 2 are highly expressed in approximately 50% of RCC cases [97]. Furthermore, HDAC3 
is overexpressed in human RCC, which makes LBH589 a potential anticancer molecule, 
through the degradation of Aurora A and Aurora B kinases, resulting in induction of G2-M arrest, 
promotion of apoptosis and suppression of tumor formation in vivo [98].  
Hypoxia is also of significant importance in regulation of histone modulators. Genes 
encoding for Jumonji family histone demethylases are a class of HIF-responsive hypoxia 
inducible genes. In fact, hypoxic cells express high JMJD1A and JMJD2B mRNA and protein 
levels and it was demonstrated that HIF-1α binds to specific sites at those genes, inducing their 
expression [99]. It was also shown that those enzymes partially retain their histone demethylase 
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activity in conditions of intense and even severe hypoxia [99]. Another study confirmed that 
JMJD1A regulates the expression of hypoxia-related genes and it may also regulate other 
specific genes by means of its demethylating activity [100]. Furthermore, class II HDACs are 
implicated in HIF-1α stability. Indeed, exposure to HDAC inhibitor LAQ824 results in inhibition 
of HIF-1α transcriptional activity, which is independent of VHL [101]. Moreover, among class II 
HDACs, HDAC4 and HDAC6 negatively regulate HIF-1α activity at transcript and protein levels 
[101]. 
Altered expression of histone modifiers might be of clinical relevance. Several studies 
have reported associations between expression levels and standard clinical and pathological 
variables, as well as patient outcome. BAP1 mutations have been associated unfavorable 
patient outcome, reflected in shorter overall survival [88, 89]. Furthermore, patients with BAP1 
mutations were significantly more likely to present with metastatic disease and advanced 
clinical stage. It has been also reported that among patients presenting with localized disease, 
those harboring BAP1 mutations had trend for shorter recurrence-free survival than patients 
with PBRM1 mutations (Gossage, 2013). In addition, PBRM1 downregulation correlated with 
advanced tumor stage, low differentiation grade and worse patient outcome, indicating that 
PBRM1-positive tumors have a better prognosis than those with PBRM1-negative tumors 
(Pawlowski, 2012). Moreover, tumors with PBRM1 mutations or mutations in BAP1, SETD2 
and JARID1A/KDM5A/RBP2 were more likely to present with advanced disease stage [88]. 
Furthermore, SETD2-mutated cases showed a high relapse rate [89] and its mutations were 
associated with advanced tumor stage [88]. EZH2 has been also associated with poor 
prognosis in RCC, as it has been reported to be an independent unfavorable marker of cancer-
specific survival in patients with metastatic or non-metastatic disease [102]. Another study 
found that EZH2 immunostaining correlated with higher Fuhrman grade, as well as a shorter 
overall and recurrence-free survival [96]. Finally, HDAC3 expression inversely associated with 
RCC pathological stage and HDAC1, HDAC2 and HDAC3 expression significantly correlated 
with tumor proliferation index [97]. 
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5. Aims of the Study 
As mentioned previously, the accurate distinction between benign and malignant RCTs 
is not feasible in all cases and this represents a challenge in clinical practice concerning the 
therapeutic approach. In fact, owing to the risk of tumor progression, in case of doubt between 
benign and malignant RCT, the option mostly includes an invasive approach, despite a 
considerable percentage of the cases (20%) are later found to be benign and might have been 
safely monitored by imaging, precluding nephrectomy.  
Epigenetics has emerged as an important field in Oncology, due to the implication of 
epigenetic alterations, such as histone modifications, in cancer development, eventually 
providing novel cancer biomarkers. The acknowledged involvement of HMTs and HDMs 
deregulation in cancer turns these enzymes into potential biomarkers not only for assisting in 
diagnosis but also for stratification of patients into clinically and therapeutically distinct groups. 
Recent data suggest that histone methylation/demethylation might be associated with 
renal tumorigenesis. Thereby, histone modifying enzymes may represent a group of molecules 
with potential clinical applicability for diagnosis of suspicious renal masses, especially the 
discrimination of benign from malignant entities, and might also provide important insights 
about tumor behavior. 
Hence, the main goal of this study was to determine which HMTs and HDMs might be 
relevant for renal tumorigenesis, focusing on the discrimination between oncocytomas and 
chRCCs. Thus, specific aims were addressed: 
1. Identify HMTs and HDMs deregulated in RCTs; 
2. Validate the identified HMTs and HDMs in a larger series of RCTs and renal 
normal tissue (RNTs) samples; 
3. Correlate expression levels of HMTs and HDMs with clinicopathological 
parameters; 
4. Assess the clinical usefulness of HMTs and HDMs as diagnostic and prognostic 
biomakers. 
5. Correlate the transcriptional expression levels of HMTs and HDMs with 
corresponding protein expression levels. 
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Because SMYD2 expression levels were found to be a potential biomarker for effective 
distinction of RCTs from RNTs and, most importantly, oncocytomas from chRCCs, we 
investigated its role in renal tumorigenesis. Thus, we further evaluated the phenotypic impact 
of SMYD2 silencing in RCC cell lines. 
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1. Clinical Samples 
1.1. Patients and Sample Collection 
In the present study, a total of 123 Renal Cell Tumors (RCTs), comprising the four most 
common subtypes (30 ccRCCs, 32 pRCCs, 31 chRCCs and 30 oncocytomas) were 
prospectively collected from patients consecutively diagnosed and submitted to partial or total 
nephrectomy at the Portuguese Institute of Oncology – Porto, Portugal, between 2001 and 
2007. As control samples, 10 Renal Normal Tissues (RNTs) were collected from morphologic 
normal kidney tissue of patients that were subjected to nephrectomy due to urothelial 
carcinoma. All specimens were immediately frozen after surgical procedure and stored at -80ºC 
for further analysis. In tumor samples, the presence of tumorous cells was confirmed by staining 
with Hematoxilin and Eosin (H&E), before the frozen sections were cut. In addition after the 
collection one slice was also H&E stained, for confirmation of sampling of more than 70% of 
malignant cells.  Histological slides from formalin-fixed paraffin-embedded (FFPE) tissue 
fragments were also obtained from the same surgical specimens and assessed for TNM stage 
and Fürhman grade. Relevant clinical data was also collected from the clinical records. This 
study was approved by the Institutional Review Board [Comissão de Ética para a Saúde-(CES-
IPOFG-EPE 518/10)] of Portuguese Institute of Oncology - Porto, Portugal. 
 
1.1.1. RNA Extraction 
Total RNA was extracted of the clinical samples, which were previously suspended in 
TRIzol reagent (Invitrogen™, Carlsbad, CA, USA) and, after addition of chloroform (EMD-
Millipore) to the lysed cells, total RNA was purified from the aqueous phase of TRIzol extract 
using the PureLink RNA Mini Kit (Invitrogen™) according to manufacturer’s recommendations. 
RNA concentrations and purity ratios were determined using a NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). When necessary, RNA 
quality was verified by electrophoresis. All RNA samples were stored at -80ºC. 
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1.1.2. Screening of Histone Methyltransferases and Demethylases 
Five RNTs and ten RCTs (five oncocytomas and five chRCCs), were selected. After 
confirming the integrity of the RNA by electrophoresis and purity ratios, samples were treated 
with TURBO DNA-free™ kit (Ambion®, Austin, TX, USA) to remove any DNA contamination. 
Then, 1 μg of total RNA was reverse transcribed using the High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems®, Foster City, CA, USA) according to the manufacturer’s 
instructions in a Veriti® Thermal Cycler (Applied Biosystems®). Custom made TaqMan® Array 
96-Well expression Plates assessing 87 histone methylation enzymes (58 HMTs and 29 HDMs) 
were purchased to Applied Biosystems® (Foster City, CA, USA). The enzymes analysed are 
summarized in Supplementary Table 1. RT-qPCR protocol was performed on an ABI-7500 
Real-Time PCR system (Applied Biosystems®) according to manufacturer’s instructions and 
each gene was run in triplicate.  
The amount of mRNAs of the analyzed genes was normalized to Glucuronidase beta 
(GUSβ) and Human 18S ribosomal RNA (18S) reference genes. The median value of RNTs 
and RCTs samples was chosen to calculate fold-difference in gene expression between 
groups, using the comparative CT method. For each gene the standard-deviation of groups 
were observed by a graphic representation and comparative CT values were used for statistical 
analysis. For each statistically significant gene, the distribution of the expression levels was 
analyzed individually among the different histological groups. The genes selected for further 
analysis were those whose expression levels followed the same trend, both in RCTs and 
chRCCs.  
 
1.1.3. Validation of selected enzymes 
After gene selection, mRNA levels were evaluated in a larger series of 123 RCTs, 
including 30 ccRCCs, 32 pRCCs, 31 chRCCs and 30 oncocytomas and 10 RNTs. A total of 
300ng was reverse transcribed and amplified using TransPlex®Whole Transcriptome 
Amplification Kit (Sigma-Aldrich®, St. Louis, MO, United States) with subsequent purification 
using QIAquick PCR Purification Kit (QIAGEN, Germany), according to manufacturer’s 
instructions. HMTs or HDMs mRNA levels were evaluated using TaqMan® Gene Expression 
Assays (Applied Biosystems®) and GUSβ and 18S were also analyzed as reference genes. 
To determine the relative expression levels in each sample, the values of the target gene were 
normalized using the median of the two internal reference genes to obtain a ratio (HMT or 
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HDM/Mean of GUSβ and 18S). Each plate included multiple non-template controls and serial 
dilutions of a cDNA Human Reference Total RNA (Agilent Technologies, La Jolla, CA, USA) to 
construct a standard curve for each plate. All experiments were run in triplicate. In Table 5 are 
displayed the Taqman® Gene Expression Assays used. 
 
Table 5 - TaqMan® Gene Expression Assays’ references of the HMTs and HDMs analyzed. 
Gene Assay Reference 
SMYD2 Hs00260120_m1 
SETD3 Hs00220210_m1 
NO66 Hs02743012_s1 
GUSB Hs99999908_m1 
18S Hs99999901_s1 
 
1.1.4. Immunohistochemistry 
Histological slides from formalin-fixed paraffin-embedded (FFPE) tissue fragments were 
obtained from the same surgical specimens previously referred, and samples were sectioned 
at a thickness of 4 μm. Briefly, after deparaffinization, antigen retrieval was performed by 
heating, in a microwave oven for 20 minutes in an antigen unmasking solution (citrate buffer) 
(Vector Laboratories, Peterborough, United Kingdom). Then, endogenous peroxidase activity 
was neutralized for 20 minutes with 0.6% hydrogen peroxide (EMD-Millipore, Massachusetts, 
USA). Protein detection was performed using the Novolink™Max Polymer Detection System 
(Leica Biosystems, Nussloch, Germany), according to manufacturer instructions. Slides were 
incubated overnight with a rabbit polyclonal antibody specific for SET and MYND domain 
containing 2 (SMYD2) (Sigma Aldrich®) in a 1:250 dilution at 4ºC and with a rabbit polyclonal 
antibody specific for SET domain containing 3 (SETD3) (Novus Biologicals®, Cambridge, 
United Kingdom) in a 1:200 dilution at room temperature, one hour, both inside a humid 
chamber. All washing steps were performed with Tris buffered saline with Tween® 20 (TBS-T) 
(Sigma-Aldrich®). Antigen-antibody binding reaction was unveiled as the slides were incubated 
for 7 minutes, in the dark, in a 0.05% (m/v) 3,3’-diaminobenzidine (DAB) solution (Sigma-
Aldrich®) in phosphate-buffered saline (PBS) (Biochrom Ltd., Cambridge, United Kingdom). 
Finally, slides were counterstained with Hematoxylin (EMD-Millipore) and dehydrated and 
diaphanized. As a positive control for the immunohistochemistry (IHC) reaction, FFPE tissue 
from a normal testis and small intestine was included for SMYD2 and SETD3, respectively. 
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Slides were observed at the optical microscope by an experienced pathologist for 
SMYD2 and SETD3 immunoexpression evaluation. The results for SMYD2 and SETD3 
expression were expressed in a semi-quantitative scale for both staining intensity (0 – no 
staining; 1 – intensity < normal kidney; 2 – intensity = normal kidney; 3 – intensity > normal 
kidney) and percentage of positive cells (0 - <10%; 1 – 10-33%; 2 – 33-67%; 3 – >67%), in 
each tumor. Individual intensity and percentage of positive cell scores were combined (intensity 
x percentage of positive cells) to assign a composite score in each tumor. Combined scores 
(Score A) were divided in a low expression group (S<4) and a high expression group (S>=4), 
comprising tumors with less than 33% of stained cells or staining intensity lower than normal 
kidney, and tumors with at least 33% of cells stained with an intensity equal or higher than 
normal kidney, respectively. 
 
1.1.5. Methylation-Specific PCR 
In order to confirm that SMYD2 was putatively regulated by methylation, it was evaluated 
the methylation status of its promoter.  
Firstly, DNA from 20 RCTs (5 ccRCCs, 5 pRCCs, 5 chRCCs and 5 oncocytomas) and 5 
RNTs clinical samples were extracted by the phenol-chloroform, according to standard 
protocol. Briefly, the digestion of tissues was the first step, by adding DNA digestion buffer 
(composed by SE solution - 75mM Sodium Chloride [EMD-Millipore and 25 mM EDTA[] and 
10% of Sodium Dodecyl Sulfate (SDS) [Sigma Aldrich®]) and proteinase K (Sigma-Aldrich®), 
followed by an overnight incubation in a water-bath at 55ºC until total digestion was achieved. 
In some cases, the incubation went for 2 to 3 days and proteinase K was added twice a day, 
until digestion was achieved. Then, phenol/chloroform solution at pH8 (Sigma Aldrich®) was 
added in Phase Lock Gel Light  tubes of 2mL (5 Prime, Deutschland, Germany) and the upper 
aqueous phase was collected to a new tube. Then, DNA precipitation was performed by adding 
100% cold ethanol, 7.5 M ammonium acetate (Sigma-Aldrich®) and 5 mg/mL glycogen 
(Applied Biosystems®), which were mixed and incubated overnight at -20ᴼC. Finally, the 
samples were washed in successive washes with 70% ethanol solution and the pellets were 
air dried and eluted in 30 μL of sterile distilled water (B. Braun, Melsungen, Germany). DNA 
concentrations were determined using a NanoDrop ND-1000 spectrophotometer (Nanodrop 
Technologies) and stored at - 20ºC until used. 
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After DNA extraction, samples were submitted to a sodium bisulfite treatment, which allow 
the identification of methylated and unmethylated cytosines. The basic principle of sodium 
bisulfite modification of DNA is that all unmethylated cytosines are deaminated, sulphonated 
and then converted to thymines, whereas methylated cytosines remain unaltered in the 
presence of Sodium Hydroxide (NaOH) and sodium bisulfite [103]. Consequently, the 
sequence of treated DNA will differ depending on whether the DNA is originally methylated or 
not, since unmethylated cytosines are converted to uracil residues and methylated cytosine 
remain as cytosines. The sodium bisulfite modification was performed using EZ DNA 
Methylation-Gold™ kit (Zymo Research, Orange, CA, USA), according manufacturer’s 
guidelines with 1 μg of DNA in a total volume of 20 μL in sterile distilled water used. The 
denaturation of samples was performed in Veriti® Thermal Cycler, using manufacturer’s 
conditions. CpGenome™ Universal Methylated DNA (EMD-Millipore, Temecula, CA, USA) and 
CpGenome™ Universal Unmethylated DNA (EMD-Millipore) were also modified to be used as 
positive and negative controls of the experiment. Finally, samples were eluted in 60µL of sterile 
distilled water and stored at -80ᴼC, while controls were eluted 30 μL and stored at -20ºC.  
Then, CpG islands were searched in 2000 bp upstream of Transcription Start Site (TSS) of 
SMYD2 and three pairs of Methylation Specific PCR (MSP) primers were designed by Methyl 
Primer Express® v 1.0. in order to screening different areas of the CpG island. Figure 10 and 
Table 6 represent the relative location of primers in the CpG island and their respective 
sequence. 
 
 
Figure 10 - Schematic representation of promoter CpG Island of SMYD2 gene and relative 
position of primers designed. 
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Table 6 - Sequence of forward and reverse primers for each pair of Methylation Specific PCR 
(MSP) primers for SMYD2 promoter gene. 
 Forward (5’-3’) Reverse (5’-3’) 
Pair 1 CGTTCGTTTCGTGGAGAC CCGTTTCCGATATAACCG 
Pair 2 CGTCGTTATTATGAGGGTC CTCGTTAACCGTAAACACG 
Pair 3 TTACGTTAGGCGTTACGTGC CCGAATTTACGCATCCAAC 
 
 MSP constitutes a sensitive and specific methodology for evaluating promoter 
hypermethylation of CpG islands [103]. For this analysis, modified DNA of 20 RCTs and 5 RNTs 
samples were used as well as positive and negative controls and one water blank. Briefly, the 
clinical samples and positive and negative controls were added to an amplification mix 
containing sterile distilled water, 10x Maxima HotStart Taq Buffer (Thermo Scientific Inc., 
Bremen, Germany), 2mM dNTPs Mix (Thermo Scientific), 25mM MgCl2 (Thermo Scientific), 
10 μM of each pair (forward and reverse) of methylated primers (Eurofins MWG Operon, 
Ebersberg, Germany) at and 2U Maxima HotStart Taq DNA Polymerase (Thermo Scientific). 
Table 7 depicts the different magnesium concentrations and annealing temperatures used for 
each pair of primers. The amplification conditions were performed at 95°C for 10 minutes, 
followed by 35 cycles at 95°C for 30 seconds, for each pair of primers an optimal annealing 
temperature (50ºC for pair 1, 54ºC for pair 2, and 52ºC for pair 3) was performed for 30 seconds 
and 72°C for 1 minute, followed by a final extension for 7 minutes at 72°C. The amplification 
products were loaded on a 2% agarose gel, stained with GreenSafe Premium (nzytech, Lisboa, 
Portugal), and visualized in VersaDoc™ Imaging System (Bio-Rad, München, Germany). 
 
Table 7 - Magnesium concentrations and Annealing Temperatures used for each pair of MSP 
primers in SMYD2 promoter gene. 
 Magnesium Concentration (mM) Annealing Temperatures (ᴼC) 
Primer Pair 1 1.5 50 
Primer Pair 2 1.5 54 
Primer Pair 3 2 52 
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2. In Vitro Studies 
2.1. Cell Culture 
Two renal cell lines were used for functional assays: 786-O and Caki-1. The 786-O cell line 
is derived from a primary clear cell adenocarcinoma, whereas Caki-1 was established from the 
metastatic site of skin of a clear cell adenocarcinoma. 
Concerning the culture media conditions, 786-O was grown using RPMI 1640 Liquid 
Medium (EMD-Millipore), while Caki-1 was maintained in McCoy’s 5A modified Liquid Medium 
(EMD-Millipore); both cell lines were supplemented with 10% of Fetal Bovine Serum (FBS) 
Superior (EMD-Millipore) and 1% Penicillin/Streptomycin (GIBCO®, Carlsbad, CA, USA) and 
maintained in cell culture flaks at 37ºC and 5% CO2 at a humidifying chamber. TrypLE™ 
Express (GIBCO®) was used in all cell harvests’ (tripsinizations). In the final of each 
experiment, both cell lines were routinely tested by a specific multiplex PCR for contamination 
by Mycoplasma spp. 
2.2. SMYD2 Silencing 
Renal cell lines, 786-O and Caki-1 cell lines were cultured in 96-well plates and 6-well plates 
and transfected with a Stealth RNAi™ siRNA Negative Control (NC) (Ambion®) and Stealth 
siRNA-SMYD2 (Ambion®). This control is designed to minimize sequence homology to any 
vertebrate cell line and it is a way to measure the effect of Stealth siRNA versus background 
as it does not produce any effects on SMYD2 function. Indeed, Stealth siRNA-SMYD2 is a new 
generation of RNAi chemistry that provides higher specificity and increased stability than 
standard siRNA, providing an effective knockdown with reduced cellular toxicity. The respective 
sequences are showed in Table 8. The in vitro experiments were performed in 96-well plates, 
and cells were grown in 6-well plates for RNA and protein collection. Before performing SMYD2 
transfection, the number of cells cultured in 96-well plates and 6-well plates were previously 
optimized as well as the conditions in which siRNA NC and siRNA-SMYD2. In fact, different 
cells per well for 96-well plates and 6-well plates were tested, which for 786-O ranged between 
2500 and 50 000 cells per milliliter and 50 000 and 500 000 cells per milliliter, for 96-well plates 
and 6-well plates, respectively. For Caki-1 the concentration varied from 5000 to 50 000 cells/ 
mL and 50 000 to 500 000 cells/mL, for 96-well and 6-well plates, respectively. Concerning the 
Materials and Methods 
 
 
 
48 
conditions of siRNA NC and siRNA-SMYD2 and as it was purchased two siRNA-SMYD2, it 
was tested different concentrations (10nM, 25nM and 50nM) for each siRNA-SMYD2 
separately and together, as well as the time course experiments. The optimized conditions for 
both cell lines are indicated in Table 9. 
 
Table 8 - Stealth siRNA-SMYD2 sequences used in this study. 
  Sequence (5’ to 3’) 
Stealth siRNA-SMYD2 #1 
Sequence 1 ACCAGGAAAGAAGGAUUGUCCAAAU 
Sequence 2 AUUUGGACAAUCCUUCUUUCCUGGU 
Stealth siRNA-SMYD2 #2 
Sequence 1 GAAGAAGGAUUUGAUUCAGAGUGAC 
Sequence 2 GUCACUCUGAAUCAAAUCCUUCUUC 
 
 
Table 9 - Optimized number of cells for 96 and 6-well plates, siRNA Negative Control and siRNA-SMYD2 
concentrations and time course experiment for 786-O and Caki-1 cell lines. 
Cell 
Line 
Number of cells per milliliter 
siRNA-NC 
(nM) 
siRNA-SMYD2 (nM) 
Time Course 
Experiment 
(h) 
96-well Plates 
(cells per mL) 
6-well Plates 
(cells per mL) 
786-O 5000 50 000 
50 
50 (siRNA-SMYD2 #1 
+ siRNA-SMYD2#2) 
72h 
Caki-1 10 000 300 000 
 
Briefly cells were cultured one day prior to transfection protocol to guarantee a 30-50% 
confluence at time of transfection. Transfection was performed, as suggested by manufacturer, 
using Oligofectamine™ Reagent (Invitrogen™), which favors an efficient and highly specific 
transfection into cells. Briefly, transfection molecules were diluted in Opti-Mem® 1x (GIBCO®) 
and simultaneously, Oligofectamine™ was added to Opti-Mem® and incubated for 10 minutes. 
Diluted transfection molecules were combined with diluted Oligofectamine™ and incubated for 
20 minutes to form complexes. Then, medium without serum and mixture of the complexes 
were added to each well with cell content. Plates were then incubated in a humidified chamber 
at 37ºC and 5% CO2 for 4 hours, and after that period it was added medium with 30% FBS to 
all plates, with the exception of plates used for proliferation experiments, which were 
maintained in chamber until the incubation with 5-bromo-2'-deoxyuridine (BrdU) labelling 
solution. Biological triplicates were performed for each condition. Cells were then incubated for 
72 hours for further phenotypic assays. 
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2.2.1. Cell Viability Assay 
In order to evaluate the impact of in vitro transfection of SMYD2 in renal cell lines viability, 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed. This 
method is based on the cleavage of yellow-colored, MTT into a blue-colored formazan by the 
mitochondrial enzyme succinate-dehydrogenase [104]. This technique is grounded on the fact 
that mitochondrial activity is constant in viable cells, and thus the reaction only occurs in living 
cells with functional mitochondria, standing as a direct measure of cell viability [104].  
Cells were seeded in 96-well plates (Sarstedt, Nümbrecht, Germany) at different 
concentrations, depending on cell line, in complete medium and incubated in a humidified 
chamber at 37ºC and 5% CO2. Cells were allowed to adhere and then viability assay was 
performed right before transfection (0 hours) and in subsequent days after transfection protocol 
(24, 48, 72 hours) at same time. Briefly, 5mg/mL MTT (Sigma-Aldrich®) diluted complete 
medium were added to each well and incubated in a humidified chamber (37ºC, 5% CO2) for 2 
hours, until the black crystal formed. Then, MTT solution was withdrawn and formazan crystals 
were dissolved DMSO (Sigma-Aldrich®) and finally plates were shaken for 15 minutes for 
complete dissolution. Absorbance levels were measured using a microplate reader (Fluostar 
Omega, BMG Labtech, Offenburg, Germany) at a wavelength of 540 nm with background 
deduction at 630 nm. Three blanks consisting of DMSO were included in each plate and optical 
density (OD) values were corrected using these blanks. Number of cells was obtained using 
the following formula: [(OD experiment x Mean Number of cells at Day 0)/Mean OD at Day 0]. 
Three biological independent experiments were performed with methodological triplicates for 
each experiment. 
 
2.2.2. Apoptosis Assays 
Apoptosis evaluation was accomplished by using the APOPercentage™ Apoptosis Assay 
(Biocolor Ltd., Belfast, Northern Ireland, UK). This assay uses a dye that is incorporated by 
cells undergoing apoptosis, based on phosphatidylserine transmembrane movements, which 
results in incorporation of the APOPercentage dye by cells in apoptosis. This assay stains initial 
stages of apoptosis process and does not stain necrotic cells.  
Cells were grown in 96-well plates at different concentrations, depending on the cell line, in 
complete medium and incubated in a humidified chamber at 37ºC and 5% CO2. One day after 
plating, cells were transfected and apoptosis assay was conducted 72 hours after transfection. 
The apoptosis assay was performed according manufacturer’s instructions. Absorbance levels 
were measured using a microplate reader (Fluostar Omega) at a wavelength of 550 nm with 
Materials and Methods 
 
 
 
50 
background deduction at 620 nm. Hydrogen peroxide 30% (Merck) was added to wells 
containing not transfected cells to serve as positive controls of apoptosis. Three blanks 
consisting of APOPercentage dye releasing agent were included in each plate and OD values 
were blank corrected. So as to normalize the OD obtained for the apoptosis assay relatively to 
the cell number, OD of cell viability assay divided this OD. The results were expressed as the 
ratio of the OD of siRNA-SMYD2 transfected cells to the siRNA NC (set as 100%). 
 
2.2.3. Proliferation Assays 
Evaluation of proliferation was performed using the Cell Proliferation ELISA, BrdU 
(Colorimetric) (Roche, Basel, Switzerland). This assay is based on the incorporation of the 
pyrimidine analogue BrdU into DNA of proliferating cells, which is then detected by 
immunoassay. The reaction product is quantified by measuring the absorbance, which directly 
correlates to the amount of DNA synthesis and thereby to the number of proliferating cells. This 
technique avoids the necessity of radioactive handling, used in the traditionally [3H]-thymidine 
incorporation techniques. 
Cells were grown in 96-well plates at different concentrations, depending on the cell line, in 
complete medium and incubated in a humidified chamber at 37ºC and 5% CO2. After 4 hours 
of transfection of siRNA NC and siRNA-SMYD2, 10µM BrdU diluted in medium with 30% of 
FBS was added to each well and plates were re-incubated in a humidified chamber at 37ºC for 
24h. The proliferation assay was performed according manufacturer’s instructions. The anti-
BrdU-POD working solution was used at a dilution of 1:100 and after the incubation with 
Substrate Solution the absorbance levels were measured using a microplate reader at a 
wavelength of 370 nm with background deduction at 492 nm. Three blanks consisting of 
Substrate Solution were included in each plate and its absorbance value does not exceed 0.1 
(as recommended by the producer) and these values were subtracted from all other values 
(blank corrected). The OD values used for the analysis were those registered until a 
stabilization of substrate incorporation.  
 
2.2.4. Invasion Assay 
To determine the impact of SMYD2 transfection on 786-O and Caki-1 cell lines invasion 
ability, it was ascertained using BD BioCoat™ Matrigel™ Invasion Chamber (BD Biosciences, 
San Jose, CA, USA). Briefly, this assay consists of inserts containing a membrane with a thin 
layer of Matrigel basement membrane matrix that mimics the basement membrane. The 
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principle of this assay consists on the fact that cells with invading characteristics will migrate 
through the membrane, overcoming the pores of the thin layer, while non-invasive cells will not. 
For Invasion Assay, cells were plated at different concentrations, depending on the cell line, 
and incubated in a humidified chamber at 37ºC and 5% CO2. After 48 hours of transfection, 
rehydration procedure was performed according manufacturer’s instructions and cells were 
collected by trypsinization. Per each chamber of invasion kit were seeded 2500 cells 
ressuspended in free-serum medium and for all wells standing below chambers cells, it was 
added medium with serum as a chemoattractant. Plates were then incubated for 24 hours in a 
humidified chamber at 37ºC and 5% CO2. After incubation period, chambers were transferred 
to methanol at 4ºC, in order to fix cells in the lower side of the insert, invading cells, for 10 
minutes at 4ºC. After this, chambers were washed with PBS and then were placed upside down 
to dry the inserts. Later, with the aid of a scalpel, inserts were cut and transferred to a slide to 
be stained with VECTASHIELD® Mounting Media containing DAPI (Vector Laboratories, Inc., 
Burlingame, CA, USA). Finally invading cells were counted using a fluorescence microscope 
and expressed in percentage, having as reference the cells of siRNA NC. Three independent 
experiments were performed for each condition with methodological duplicates.  
 
2.2.5. RNA Extraction and SMYD2 Evaluation Transcriptional Expression 
For RNA extraction, cells were cultured and transfected in 6-well plates. After 72 hours of 
transfection, cells’ pellets were collected and stored at -80ºC. Total RNA from cell lines was 
extracted by TRIzol® Reagent and homogenized with a 19G needle. After that, chloroform and 
isopropanol (EMD-Millipore) was added for RNA separation and precipitation, respectively and 
then successive washes with 70% ethanol was performed. Finally, RNA pellets were air dried, 
eluted in RNA Storage Solution (Ambion®) and stored at -80ºC. RNA concentrations and purity 
ratios were determined using a NanoDrop ND-1000 spectrophotometer.  
In order to evaluate SMYD2 transcript expression in 786-O and Caki-1 cells upon silencing 
protocol, 1 μg of total RNA was reverse transcribed using the High Capacity cDNA Reverse 
Transcription kit according to the manufacturer’s instructions. Moreover, SMYD2 transcriptional 
levels were quantified by RT-qPCR using 7500 Real-Time PCR system in samples transfected 
with siRNA NC and siRNA-SMYD2. The Taqman® Gene Expression Assay for SMYD2 was 
the same as previously used. Each sample was run in triplicate and two negative template 
controls were included in each plate. GUSβ and 18S were used as reference genes. 
Analysis of SMYD2 silencing was performed using comparative CT method, where siRNA 
NC expression levels were used to normalize siRNA-SMYD2 expression levels. 
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2.2.6. Protein Extraction and SMYD2 Evaluation Protein Levels 
Cell lines were cultured and transfected in 6-well plates. After 72 hours of transfection, 
protein extraction from cell lines was made using the Radio Immuno Precipitation Assay (RIPA) 
(Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). Briefly, growth medium was withdrawn 
and cells were then washed with 1x PBS. After that procedure, RIPA buffer (100mM PMSF 
solution, 100mM sodium orthovanadate solution and 25x Protease Inhibitor Cocktail Solution 
per mL of 1x RIPA lysis buffer) were added, and then cells were scrapped to promote lysis and 
removal. Cells were placed on ice and after centrifuged, the supernatant was collected. 
Protein concentration was ascertained by the Pierce BCA Protein Assay Kit (Thermo 
Scientific Inc., Waltham, MA, USA). This assay is a detergent-compatible formulation based on 
bicinchoninic acid (BCA) used for the colorimetric detection and quantitation of total protein. 
Protein concentrations were calculated using standards of bovine serum albumin (BSA) as 
references. Serial dilutions were prepared from this protein and measured together with cell 
lines samples. The procedure was performed according manufacturer’s instructions. The 
samples were transferred 96-well plates and absorbance levels were measured at 562 nm on 
a microplate reader. Proteins were stored and kept at -80ºC. 
 In order to evaluate SMYD2 protein level in 786-O and Caki-1, Western-Blot was 
performed. Briefly, 20 and 30 µg of total protein for 786-O and Caki-1, respectively, were 
ressuspended in loading buffer and denaturated at 95ºC. Proteins were then separated by 
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) on 10% 
polyacrylamide gels at 120 V at room temperature and subsequently blotted into Protan 
nitrocellulose transfer membranes (Whatman, Dassel, Germany) at 50V for 1 hour at 4ºC. After 
electroblotting, the membranes were incubated in blocking buffer (5% nonfat dry milk in Tris-
buffered saline containing TBST) with agitation. The membranes were then incubated overnight 
at 4ºC with the primary polyclonal rabbit antibody for SMYD2 (Abcam, Cambridge, United of 
Kingdom), diluted 1:1000 in blocking buffer. After washing steps, the membranes were 
incubated for 1 hour at room temperature with horseradish peroxidase conjugated secondary 
anti-rabbit antibody (Bio-Rad) diluted 1:4000 in blocking buffer. After washing, the membranes 
were developed using Immuno-Star WesternC Chemiluminescent Kit (Bio-Rad) and exposed 
to Amersham Hyperfil (GE HealthCare, Buckinghamshire, UK). 
To establish equal loading of protein, the membranes were stripped using and reprobed with 
an antibody against the lading control (B-Actin). The membranes were incubated for 15 minutes 
in EZWay™Antibody Erasing Buffer (Komabiotech, Seoul, South Korea) with vigorous agitation 
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and washed with distillated water. After blocking, the membranes were incubated with a 
monoclonal mouse antibody against B-Actin (Sigma-Aldrich) diluted 1:8000 for 30 minutes at 
room temperature. After washing, the membranes were incubated for 15 minutes at room 
temperature with horseradish peroxidase conjugated secondary anti-mouse antibody (Bio-
Rad) diluted in 1:3000. After washing, membrane developing was performed as mentioned 
above. 
 
2.2.7. Expression Assays 
Retinoblastoma 1 (RB1), TP53, MDM2 proto-oncogene (MDM2) and Cyclin-dependent 
Kinase Inhibitor 1A (CDKN1A or p21) genes identified as regulators of the cell cycle and 
apoptosis pathways were quantified and validated by RT-qPCR in siRNA NC and siRNA-
SMYD2 transfected cells. Validation was performed using expression assays based on 
Taqman technology for RB1 and specific primers sequences based on SYBR GREEN 
technology for TP53, MDM2 and p21, as shown in Table 10. Reactions were carried out in 96-
well plates using a 7500 Sequence Detection System. The procedure both for Taqman and 
SYBR Green was conducted according manufacturer’s instructions. All samples were run in 
triplicate and two negative template controls were included in each plate. GUSβ and 18S were 
used as reference genes. Analysis of genes expression was performed using comparative CT 
method, where siRNA NC expression levels were used to normalize siRNA-SMYD2 expression 
levels. 
 
Table 10 - Specific Sequence Primers and Exression Assays used to evaluate the gene expression of 
regulators of cell cycle and apoptosis pathways. 
SYBR Green Technology 
 Forward (5’-3’) Reverse (5’-3’) 
TP53 AGCAGGGCTCACTCCAGC GTCAGGCCCTTCTGTCTTGA 
MDM2 CCGGATCTTGATGCTGGTGT CTGATCCAACCAATCACCTGAAT 
P21 AGCGATGGAACTTCGACTTTG CGAAGTCACCCTCCAGTGGT 
Taqman Technology 
RB1 Hs01078066_m1 
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3. Statistical Analysis 
In this work, non-parametric tests were used to ascertain statistical significance for 
comparisons made. Kruskal-Wallis test (KW) was used for comparisons between multiple 
groups (more than 2) and Mann-Whitney U test (MW) was used in pairwise comparisons. These 
tests were used both in clinical samples and in vitro studies. The chi-square test or Fisher’s 
exact test were used to reveal differences in the frequency protein expression according to 
immunohistochemical score for SMYD2 and SETD3, among the four RCT types. 
To ascertain correlation values between age and HMTs and HDMs expression levels, a 
Spearman Nonparametric Correlation Test was carried out.  
In order to assess the diagnostic performance of different biomarkers, a Receiver Operator 
Characteristics (ROC) curve was constructed by plotting the true positive rate (sensitivity) 
against the false positive rate (1-specificity) and the area under the curve (AUC) was calculated. 
The sensitivity, specificity, positive and negative predictable values and accuracy were 
calculated based on a cutoff value obtained by ROC curve analysis, with higher values for both 
sensitivity and specificity, emphasizing the latter. 
The prognostic significance of available clinical variables (histological subtype, pathological 
stage, Fuhrman grade, age, gender and also HMTs and HDMs expression levels) was 
assessed by constructing disease-specific and metastasis-free survival curves using the 
Kaplan-Meier method with log-rank test (univariable test). The expression levels of SMYD2, 
SETD3 and NO66 were classified as low or high based on the cutoff value of 25th percentile for 
expression of each enzyme. A Cox-regression model using Forward Stepwise test comprising 
the different variables (multivariable test) was also constructed. For metastasis-free survival 
analysis 88 RCC patients were included, which comprised all RCCs subtypes, while for 
disease-specific survival follow-up data from 62 patients was used, only comprising pRCC and 
ccRCC patients, as those are the histological subtypes that presented death events. 
P-values were considered statistically significant when inferior to 0.05 for comparisons 
between two groups and when comparing multiple groups, Bonferroni correction was applied 
in subsequent paired comparisons, dividing P-value by number of groups evaluated (p value < 
0.05/n). 
Statistical analyses were performed using SPSS software for Windows, version 22.0 (IBM-
SPSS Inc., Chicago, IL, USA). Graphs were built using GraphPad Prism 6.0 software for 
Windows (GraphPad Software Inc., La Jolla, CA, USA).
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1. Evaluation of Histone Methyltransferases and 
Demethylases Expression Levels 
1.1. Screening of Histone Methyltransferases and Demethylases 
To identify enzymes involved in histone methylation, deregulated in RCTs, expression 
levels of 58 HMTs and 29 HDMs were evaluated in 5 chRCCs, 5 oncocytomas and 5 RNTs. 
The analysis was performed by comparing RNTs and RCTs as well as chRCCs and 
oncocytomas. Globally, HMTs upregulation was observed in RCTs compared to RNTs (Figure 
11). Conversely, in most cases, HMTs and HDMs expression levels were downregulated in 
chRCCs compared to oncocytomas (Figure 12). 
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Figure 11 - Expression levels of 52 HMTs and 29 HDMs 
in five renal normal tissues (RNTs) and ten renal cell 
tumors (RCTs). Gene expression was calculated using 
comparative CT method and the ΔΔCT using 18S and 
GUSβ as endogenous control genes and RNTs as control 
group. Each sample was run in triplicate. The results 
presented correspond to median value of each group. 
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Figure 12 - Expression levels of 52 HMTs and 29 HDMs 
in five Oncocytomas and five chromophobe renal cell 
carcinomas (chRCCs). Gene expression was calculated 
by comparative CT method and the ΔΔCT using 18S 
and GUSβ as endogenous control genes and 
Oncocytomas as control group. Each sample was run in 
triplicate. The results presented correspond to median 
value of each group. 
 
PRDM4, PRMT5, SETD3, SETDB2, SETMAR, SMYD2, SUV39H1, SUV420H2, 
KDM4B, KDM4E, KDM6B, MINA, NO66 and PADI4 showed significantly different expression 
levels between RCTs and RNTs (Table 11). Subsequently, SMYD2, SETD3 and NO66 were 
selected for validation, because they were simultaneously overexpressed in RCTs compared 
to RNTs and in chRCCs compared to oncocytomas (Figure 13). 
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Table 11 - Mann-Whitney p value obtained for HMTs and HDMs 
analyzed, comparing RCTs and RNTs. The ΔCT value of each sample 
was calculated using 18S and GUSβ as endogenous reference genes. 
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Figure 13 - Fold variation of HMTs and HDMs expression levels in RNTs and RCTs (A) 
and Oncocytomas and chRCCs (B). The HMTs and HDMs represented were those whose 
expression was significantly different between RCTs and RNTs. Fold variation was 
calculated using RNTs (A) or Oncocytomas (B) as controls. The Standards Deviations for 
RNTs and RCTs were calculated using the following formulas (2(-ΔΔCT[RNTs]±SD[RNTs])/2(-
ΔΔCT[RNTs])) and (2(-ΔΔCT[RCTs]±SD[RCTs])/2(-ΔΔCT[RNTs])), respectively. The same formulas were 
used for comparison of chRCCs and Oncocytomas. 
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1.2. Validation of Selected Enzymes 
The validation of SMYD2, SETD3 and NO66 was performed by quantitative RT-PCR in a 
larger series of RCTs and RNTs. The results were fully concordant with those of the TaqMan® 
Array. Indeed, all enzymes were significantly overexpressed in RCTs compared to RNTs 
(p<0.001 for all; Figure 14 A-C).  
 
Figure 14 - Expression levels of SMYD2 (A), SETD3 (B) and NO66 (C) in a 
larger number of RCTs (n=123) and RNTs (n=10) (**** p<0.0001; *** 
p<0.001). 
 
Moreover, expression levels of SETD3 and NO66 differed significantly between benign and 
malignant RCTs (Figure 15 B-C).  
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Figure 15 - Expression levels of SMYD2 (A), SETD3 (B) and NO66 (C) in a larger 
number of benign tumors (Oncocytomas, n=30) and malignant tumors (Renal Cell 
Carcinomas [RCCs], n=93). No statistical association was found for SMYD2 (*** 
p<0.001; ** p<0.01). 
 
Expression levels of all enzymes differed significantly among the four RCT subtypes (Table 
12). For all enzymes, chRCC displayed the highest expression levels, followed by oncocytoma 
(Figure 16 and Table 13). Conversely, pRCC and ccRCC showed the lowest expression levels, 
although those were higher than that of RNTs (Figure 16). 
 
Table 12 - Pairwise comparison of SMYD2, SETD3 and NO66 
expression among renal cell tumor subtypes in fresh-frozen tissues 
using Mann-Whitney test (M-W test). The values were statistically 
significant when p<0.0125 (Bonferroni’s correction) and these are 
represented in bold. 
  SMYD2 SETD3 NO66 
ccRCCs vs pRCCs 6.02x10-1 8.22x10-1 3.45x10-1 
ccRCCs vs chRCCs 3.28x10-7 2.00x10-6 5.70x10-5 
ccRCCs vs Oncocytomas 5.20x10-3 1.00x10-6 3.00x10-6 
pRCCs vs chRCCs 1.10x10-5 4.70x10-5 7.65x10-3 
pRCCs vs Oncocytomas 9.10x10-2 1.89x10-4 5.03x10-4 
chRCCs vs Oncocytomas 1.40x10-4 2.92x10-1 2.86x10-1 
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Figure 16 - Distribution of SMYD2 (A), SETD3 (B) and NO66 (C) expression levels 
according to renal cell tumor subtype. Bonferroni correction was applied and p value was 
adjusted to 0.0125 (**** p<0.0001; *** p<0.001; ** p<0.01). 
 
Table 13 - Expression levels of SMYD2, SETD3 and NO66 according to RCT subtype.  
 
SMYD2 
Mean (Minimum-
Maximum) 
SETD3 
Mean (Minimum-
Maximum) 
NO66 
Mean (Minimum-
Maximum) 
Oncocytomas 1273.49 (238.96-3363.48) 429.29 (103.16-671.17) 906.44 (283.03-3361.80) 
chRCCs 2402.23 (378.54-6230.62) 503.26 (92.73-1438.55) 915.31 (252.99-2386.39) 
pRCCs 906.03 (11.15-2885.94) 141.04 (5.92-1254.68) 501.49 (2.99-2769.28) 
ccRCCs 684.62 (291.90-2899.24) 147.42 (11.22-848.91) 356.43 (19.93-1718.67) 
 
Pair-wise comparisons showed that chRCCs significantly differed from pRCCs and 
ccRCCs, for all enzymes, whereas in oncocytomas expression levels only differed significantly 
from those of ccRCC. Furthermore, oncocytomas showed significantly higher levels of SETD3 
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and NO66 than pRCC. Importantly, SMYD2 transcript levels differed significantly between 
chRCCs and oncocytomas (Figure 16 A-C and Table 13). 
1.3. Diagnostic Performance of Selected Enzymes 
The performance of SMYD2, SETD3 and NO66 was assessed in three different settings: 
identification of RCTs, discrimination of malignant from benign tumors and distinction of 
chRCCs from oncocytomas. For that purpose, the cutoff value was set based on the highest 
value obtained by ROC curve analysis [sensitivity + (1-specificity)], prioritizing specificity.  
SMYD2 showed the best performance in discriminating RCTs from normal kidney, with 
82.1% sensitivity and 100% specificity, corresponding to an Area Under the Curve (AUC) of 
0.959 (Table 14 and Figure 17). 
 
Table 14 - Performance of SMYD2, SETD3 and NO66 in discriminating RCTs from RNTs. The cutoff values used 
were based on mRNA expression levels and were different for all three enzymes. 
Discrimination Parameters 
SMYD2 
(%) 
SETD3 
(%) 
NO66 
(%) 
RCTs from RNTs 
Sensitivity 82.1 85.4 75.6 
Specificity 100.0 80.0 100.0 
Positive Predictive Value 100.0 98.1 100.0 
Negative Predictive Value 31.3 30.8 25.0 
Accuracy 83.5 85.0 77.4 
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Figure 17 - Receiver operator characteristic (ROC) curves evaluating 
performance of SMYD2 (A), SETD3 (B) and NO66 (C) expression as biomarkers 
for discrimination between RCTs and RNTs (AUC: area under the curve). 
 
However, the performance of all genes to differentiate malignant from benign tumors 
was rather limited. Indeed, the highest AUC value (0.728) was obtained for NO66, with a 
sensitivity and specificity of 60.0 and 65.6%, respectively (Table 15 and Figure 18). 
 
Table 15 - Performance of SMYD2, SETD3 and NO66 in discriminating Malignant from Benign Tumors. The cutoff 
values used were based on mRNA expression levels and were different for all three enzymes. 
Discrimination Parameters 
SMYD2 
(%) 
SETD3 
(%) 
NO66 
(%) 
Malignant Tumors 
from Benign 
Tumors 
Sensitivity 40.0 60.0 60.0 
Specificity 62.4 67.7 65.6 
Positive Predictive Value 25.5 37.5 36.0 
Negative Predictive Value 76.3 84.0 83.6 
Accuracy 56.9 65.9 64.2 
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Figure 18 - Receiver operator characteristic (ROC) curves evaluating performance 
of SMYD2 (A), SETD3 (B) and NO66 (C) as biomarkers for discrimination between 
malignant and benign renal cell tumors (AUC: area under the curve). 
 
 Finally, SMYD2 expression levels were able to distinguish chRCCs from oncocytomas 
with 71.0% sensitivity and 73.3% specificity, corresponding to an AUC of 0.784 (Table 16 and 
Figure 19). 
 
Table 16 - Validity estimates for SMYD2, SETD3 and NO66 in discriminating chRCCs from Oncocytomas. The cutoff 
values used were based on mRNA expression levels and were different for all three enzymes. 
Discrimination Parameters 
SMYD2 
(%) 
SETD3 
(%) 
NO66 
(%) 
chRCCs and 
Oncocytomas 
Sensitivity 71.0 41.9 51.6 
Specificity 73.3 86.7 50.0 
Positive Predictive Value 73.3 76.5 51.6 
Negative Predictive Value 71.0 59.1 50.0 
Accuracy 72.1 63.9 50.8 
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Figure 19 - Receiver operator characteristic (ROC) curves evaluating performance 
of SMYD2 (A), SETD3 (B) and NO66 (C) as biomarkers for discrimination between 
chRCCs and Oncocytomas (AUC: area under the curve). 
 
1.4. Association between gene expression and clinicopathological 
features 
The clinical and pathological characteristics of patients included in this study are depicted 
in Table 17. 
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Table 17 - Clinical and Pathological data of patients included in the present study. 
 RCTs RNTs 
Number of Patients, n 123 10 
Age at diagnosis, median 
(min-max) 
60 (29-83) 67.5 (20-83) 
Gender, n (%)   
Male 74 (60,2) 7 (70.0) 
Female 49 (39.8) 3 (30.0) 
Histological Subtype, n (%)   
ccRCC 30 (24.4) 
N.A. 
pRCC 32 (26.0) 
chRCC 31 (25.2) 
Oncocytoma 30 (24.4) 
Pathological Stage, n (%)   
pT1 47 (38.2) 
N.A. 
pT2 20 (16.3) 
pT3 26 (21.1) 
pT4 0 (0) 
N.A. 30 (24.4) 
Fuhrman Grade, n (%)   
1 3 (2.4) 
N.A. 
2 29 (23.6) 
3 45 (36.6) 
4 16 (13.0) 
N.A. 30 (24.4) 
 
 No significant differences in gender were apparent between patients and controls. In 
malignant tumors, no statistically significant associations were disclosed between SMYD2, 
SETD3 or NO66 expression levels and Fuhrman categories or pathological stage. In RCTs, 
SMYD2, SETD3 and NO66 expression levels were significantly higher in females (Figure 20). 
Moreover, expression levels were significantly associated with patient’s age [SMYD2 
(p=0.004), SETD3 (p=0.001) and NO66 (p=0.001)]. 
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Figure 20 - Distribution of SMYD2 (A), SETD3 (B) and NO66 (C) expression 
levels in renal cell tumors by gender (** p<0.01; * p<0.05). 
 
1.5. Survival analysis 
 The median follow-up of RCC patients was 72 months (range: 1-90 months). A total of 
8 patients have died from RCC during this period. Disease-specific survival (DSS) analysis 
showed that low levels of SMYD2, SETD3 and NO66 were significantly associated with worse 
outcome (p=0.015, p<0.001 and p=0.009, respectively; Figure 21). Moreover, in univariate 
analysis, higher pathological stage (pT3) and Führman grade (grade 4) as well as the pRCC 
subtype were associated with a shorter survival (Supplementary Figure 1). Gender and the 
median age at diagnosis did not disclose any prognostic value within the available follow-up 
time. 
Results 
 
 
71 
 
Figure 21 - Kaplan-Meier estimated disease-specific survival curves of 62 RCC 
patients according to expression levels of SMYD2 (A), SETD3 (B) and NO66 (C). The 
results of RT-qPCR presented were categorized using first quartile (25th percentile) 
value as cutoff. 
 
However, in multivariate analysis, no parameter reached statistically significance. A 
model for assessment of prognostic value, based on an automatic variable selection algorithm 
(Forward Stepwise), was performed. Thus, a final model including SETD3 expression levels 
and Führman grade was predictive of disease specific survival and a higher risk of death was 
defined for patients harboring Führman grade 4 tumors and lower SETD3 expression levels 
(Table 18). 
 
Table 18 – Prognostic factors in Disease-Specific Survival obtained by Cox regression multivariable analysis using 
Forward Stepwise method.  The high and low levels of SETD3 mRNA expression were categorized using 25th 
percentile value as cutoff.  
Prognostic Factor 
Hazard Ratio 
(HR) 
95% CI for 
HR 
Cox Regression p 
value 
SETD3 Expression (low levels vs high 
levels) 
7,669 1.299-45.289 0.025 
Führman grade - - 0.023 
Grade 1+2 (vs Grade 4) 0.097 0.008-1.188 0.068 
Grade 3 (vs Grade 4) 0.122 0.025-0.594 0.009 
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Concerning metastasis-free survival, lower SMYD2, SETD3 and NO66 expression 
levels were significantly associated with a worse outcome (p=0.003, p=0.002 and p<0.001, 
respectively; Figure 22). Pathological stage, Führman grade, histological subtype, age and 
gender did not disclose any statistically significant association with disease progression.  
 
Figure 22 - Kaplan-Meier estimated metastasis-free survival curves of 88 RCC 
patients according to expression levels of SMYD2 (A), SETD3 (B) and NO66 (C). 
The results of RT-qPCR were categorized using 25th percentile value as cutoff. 
 
Furthermore, in multivariable analysis (Forward Stepwise) with all variables mentioned 
above, only NO66 expression levels predicted metastization, as patients with lower levels of 
NO66 had almost 12-fold increased risk to develop metastasis (Table 19).  
 
Table 19 - Prognostic factors in Metastasis-free Survival obtained by Cox regression multivariable analysis using 
Forward Stepwise method.The high and low levels of NO66 mRNA expression were categorized using 25th 
percentile value as cutoff. 
Prognostic Factor 
Hazard Ratio 
(HR) 
95% CI for HR 
Cox Regression p 
value 
NO66 expression (low levels vs high 
levels) 
11.6 2.43-56.15 0.002 
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1.6. Immunohistochemistry 
Immunohistochemistry (IHC) for assessment of SMYD2 and SETD3 protein levels was 
performed in representative tissues from the same cases used for validation of expression 
levels (RCT=123 and RNTs=10). For each tumor, scores for intensity and percentage of 
positive cells were evaluated. The intensity score is illustrated in Figure 23 and it was assigned 
by comparing the staining intensity of tumors with proximal renal tubules.  
 
 
Figure 23 - Intensity Score for SMYD2 (A) and SETD3 (B) protein expression by 
immunohistochemical analysis. Original magnification, x200. 
 
As expected, immunoreactivity for SMYD2 and SETD3 was observed in the cytoplasm. 
In normal parenchyma, SMYD2 and SETD3 expression was found in tubular epithelia, and 
distal tubules usually had a more intense staining than proximal tubules (Figure 24).  
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Figure 24 - SMYD2 (A) and SETD3 (B) protein expression by 
immunohistochemical analysis in normal kidney (original magnification: 
x200) 
The results of immunostaining scoring for SMYD2 and SETD3 are summarized in Table 
20 and Table 21. Scores for intensity and percentage of positive cells were combined to provide 
the Score A. 
 
Table 20 - Immunohistochemical results (staining intensity, percentage of positive cells and Score A, resulting from 
the combination of the two primary scores) for SMYD2 (Oncocytomas=30, chRCCs=31, pRCCs=32, ccRCCs=30). 
SMYD2 Evaluation 
Oncocytomas 
n (%) 
chRCCs 
n (%) 
pRCCs 
n (%) 
ccRCCs 
n (%) 
Intensity 
0: negative - - 3 (2.4) 5 (4.1) 
1: <RNTs 2 (1.6) 5 (4.1) 14 (11.4) 4 (3.3) 
2: =RNTs 27 (22.0) 24 (19.5) 15 (12.2) 17 (13.8) 
3: >RNTs 1 (0.8) 2 (1.6) - 4 (3.3) 
Percentage of 
positive cells 
0: <10% - - 3 (2.4) 5 (4.1) 
1: 10-33% - - 8 (6.5) 1 (0.8) 
2: 33-67% 12 (9.8) 4 (3.3) 12 (9.8) 15 (12.2) 
3: >67% 18 (14.6) 27 (22.0) 9 (7.3) 9 (7.3) 
Score A 
Low 
Expression 
2 (1.6) 5 (4.1) 23 (18.7) 9 (7.3) 
High 
Expression 
28 (22.8) 26 (21.1) 9 (7.3) 21 (17.1) 
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Table 21 - Immunohistochemical results (staining intensity, percentage of positive cells and Score A, resulting from 
the combination of the two primary scores) for SETD3 (Oncocytomas=30, chRCCs=31, pRCCs=32, ccRCCs=30). 
SETD3 Evaluation 
Oncocytoma 
n (%) 
chRCC 
n (%) 
pRCC 
n (%) 
ccRCC 
n (%) 
Intensity 
0: negative - - 1 (0.8) - 
1: <RNTs - 2 (1.6) 10 (8.1) 13 (10.6) 
2: =RNTs 10 (8.1) 6 (4.9) 8 (6.5) 8 (6.5) 
3: >RNTs 20 (16.3) 23 (18.7) 13 (10.6) 9 (7.3) 
Percentage of 
positive cells 
0: <10% - - 1 (0.8) - 
1: 10-33% - - - 2 (1.6) 
2: 33-67% 10 (8.1) 13 (10.6) 15 (12.2) 18 (14.6) 
3: >67% 20 (16.3) 18 (14.6) 16 (13.0) 10 (8.1) 
Score A 
Low 
Expression 
- 2 (1.6) 11 (8.9) 13 (10.6) 
High 
Expression 
30 (24.4) 29 (23.6) 21 (17.1) 17 (13.8) 
 
Comparing SMYD2 and SETD3 transcript and protein levels, a significant association 
was found using Score A (Figure 25). Differences between mRNA expression levels and the 
Score A groups (high and low expression) were statistically significant for SMYD2 and SETD3 
(p=0.002 and p=0.008, respectively). Moreover, Score A was significantly different between 
benign and malignant RCTs for SMYD2 (p=0.001) and SETD3 (p<0.001). Among RCTs, 
chRCC and oncocytomas generally displayed higher staining intensity and/or percentage of 
positive cells, compared to ccRCC and pRCC, following the same trend depicted for mRNA 
expression levels. 
 
 
Figure 25 - Distribution of SMYD2 (A) and SETD3 (B) mRNA expression levels in 
RCTs according to low and high protein expression assessed by 
Immunohistochemical (IHC) Score A. 
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2. Exploring the role of SMYD2 in Renal 
Tumorigenesis 
To obtain an expression profile of SMYD2 in renal cancer cell lines (Caki-1, 786-O, 
Caki-2 and ACHN), quantitative RT-PCR was performed (Figure 26). SMYD2 mRNA 
expression was higher in Caki-1 and 786-O, and, thus, these cell lines were selected for 
phenotypic assays. 
 
Figure 26 - SMYD2 expression levels in renal cancer cell lines. 
Results were normalized to ACHN. 
 
2.1. Effects of SMYD2 Silencing in 786-O cell line 
To assess the phenotypic effect of SMYD2 silencing, transient transfection of SMYD2 
was performed in 786-O cells. A 76% decrease in expression was achieved by combining the 
two short-interfering RNAs targeting SMYD2 at concentration of 50nM, comparing with siRNA 
negative control (Figure 27A). A significant reduction in protein levels was also confirmed 
(Figure 27B). 
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Figure 27 - Relative expression of SMYD2 at mRNA (A) and protein (B) levels in 
786-O cells. Gene expression was calculated using comparative CT method and 
the ΔΔCT using 18S and GUSβ as endogenous control genes and siRNA NC as 
control group. Three biological independent experiments were performed, each of 
them run in triplicate 
 
2.1.1. Impact of SMYD2 silencing in cell viability, proliferation, apoptosis and 
invasion 
 
SMYD2 silencing was significantly associated with increased proliferation (Figure 28B) 
and decreased apoptosis (Figure 28C), after 72 hours of transfection. Concerning cell viability 
and invasion, no statistically significant alterations were apparent (Figure 28A and D).  
 
Figure 28 - Impact of SMYD2 silencing in malignant phenotype of 786-O cells. (A) Cell viability 
assay, quantifying the number of viable cells in siRNA NC and siRNA-SMYD2 transfected cells at 
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different timepoints. (B) 5-bromo-2'-deoxyuridine (BrdU) incorporation in siRNA NC and siRNA-
SMYD2 transfected cells at 24 hours, 48 hours and 72 hours. (C) Quantification of apoptosis in 
siRNA NC and siRNA-SMYD2 transfected cells at 72 hours. (D) Invasive ability of siRNA NC and 
siRNA-SMYD2 transfected cells at 72 hours after transfection. Results of cell viability, apoptosis 
and invasion assays were normalized to siRNA NC cells; Data obtained from proliferation assay 
was blank corrected (** p<0.01). 
 
2.1.2. Altered expression of genes involved in pathways affected by SMYD2 
silencing 
Expression levels of key genes involved in cell cycle regulation and apoptosis pathways 
(TP53, p21, MDM2 and RB1) was assessed after SMYD2 silencing in 786-O cells. Only TP53 
showed a statistically significant downregulation in knockdowned cells compared to siRNA NC 
cells (Figure 29). 
 
Figure 29 - Expression levels of genes involved in cell cycle and apoptosis pathways in 
siRNA NC and siRNA-SMYD2 transfected 786-O cells. TP53 (A), p21 (B), MDMD2 (C) 
and RB1 (D) gene expression was calculated using comparative CT method and GUSβ 
was used as endogenous control gene. RB1 expression utilized Taqman technology and 
it used 18S and GUSβ as endogenous controls. For all genes, siRNA NC was used as 
control group. Three biological independent experiments were performed, each of them 
run in triplicate. 
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2.2. Effects of SMYD2 Silencing in Caki-1 cell line 
In Caki-1 cells, 95% of silencing was attained using siRNA-SMYD2 particles together at 
50nM (Figure 30A). A significant reduction in protein levels was also observed (Figure 30B). 
 
Figure 30 - Relative expression of SMYD2 at mRNA (A) and protein (B) levels in 
Caki-1 cells. Gene expression was calculated using comparative CT method and the 
ΔΔCT using 18S and GUSβ as endogenous control genes and siRNA NC as control 
group. Three biological independent experiments were performed, each of them run 
in triplicate. 
 
2.2.1. Impact of SMYD2 Silencing in cell viability, proliferation, apoptosis and 
invasion 
 A statistically significant decrease in the number of viable cells was observed after 
SMYD2 silencing in Caki-1 cell line, at 48 hours (15%) and 72 hours (41%) (Figure 31A). 
Furthermore, cells with SMYD2 knockdown showed a significant reduction in BrdU 
incorporation, reflecting a decline in proliferation index (Figure 31B). Moreover, 72 hours after 
transfection, apoptosis levels were statistically increased (63%) (Figure 31C). Furthermore, 
invasion capability was also affected by SMYD2 silencing, with a 70% reduction (Figure 31D). 
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Figure 31 - Impact of SMYD2 silencing in malignant phenotype of Caki-1 cells. (A) Cell viability assay, 
quantifying the number of viable cells in siRNA NC and siRNA-SMYD2 transfected cells at different 
timepoints. (B) 5-bromo-2'-deoxyuridine (BrdU) incorporation in siRNA NC and siRNA-SMYD2 
transfected cells at 24 hours, 48 hours and 72 hours. (C) Quantification of apoptosis in siRNA NC 
and siRNA-SMYD2 transfected cells at 72 hours. (D) Invasive ability of siRNA NC and siRNA-SMYD2 
transfected cells at 72 hours after transfection. Results of cell viability, apoptosis and invasion assays 
were normalized with siRNA NC cells; Data obtained from proliferation assay was blank corrected (* 
p<0.05; ** p<0.01). 
 
2.2.2. Altered expression of genes involved in pathways affected by SMYD2 
Silencing 
Expression levels of key genes involved in cell cycle regulation and apoptosis pathways 
(TP53, p21, MDM2 and RB1) were assessed after SMYD2 silencing in Caki-1 cells. All genes 
disclosed a statistically significant downregulation in cells transfected with siRNA-SMYD2 
compared to siRNA NC (Figure 32) 
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Figure 32 - Expression levels of genes involved in cell cycle and apoptosis pathways in 
siRNA NC and siRNA-SMYD2 transfected Caki-1 cells. TP53 (A), p21 (B), MDMD2 (C) 
and RB1 (D) gene expression was calculated using comparative CT method and GUSβ 
was used as endogenous control gene. RB1 expression utilized Taqman technology and 
it used 18S and GUSβ as endogenous control genes. For all genes siRNA NC was used 
as control group. Three biological independent experiments were performed, each of 
them run in triplicate. 
 
2.3. Methylation-Specific PCR 
To assess whether SMYD2 gene expression might be regulated by promoter 
methylation, MSP was performed using three different primer pairs targeting different regions 
of SMYD2 CpG islands. No methylation was found in regions targeted by primer pair 1 or primer 
pair 2. Furthermore, primer pair 3, targeting the region immediately downstream of TSS, which 
was previously demonstrated to be regulated by methylation, did not disclose differences in 
methylation patterns between RCT and RNT. 
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Renal cell tumors (RCTs) are the most lethal of the common urological cancers. 
Currently, the incidental detection of RCTs is increasing due to the widespread use of 
imagiology, mostly for investigation of non-related diseases. The correct classification of these 
small masses into benign or malignant tumors by imagiology and other techniques is 
challenging, implying that, in doubt, surgical removal is the therapy of choice, eventually leading 
to overtreatment of benign tumors or non-neoplastic conditions. Thus, efforts to discover and 
validate biomarkers capable of accurately discriminating between benign and malignant renal 
tumors are underway and are likely to have a strong impact in clinical practice. In this context, 
epigenetic-based biomarkers hold the promise to assist in diagnosis and to help stratify patients 
into clinically meaningful subgroups, bearing distinct prognosis and response to targeted 
therapy. Among epigenetic mechanisms, histone post-translational modifications and 
chromatin modulators play a critical role in gene expression regulation and its deregulation is 
likely to affect multiple cellular pathways, fostering cancer initiation and progression. Evidence 
of widespread deregulation of chromatin status in RCTs has been accumulating over the years, 
and several defects in epigenetic enzymes, including those responsible for chromatin 
packaging, histone modification and chromatin remodeling have been reported, reflecting the 
importance of those mechanisms in renal tumorigenesis [105, 106]. In this study, we 
investigated whether altered histone methylation patterns might play a relevant role in renal 
tumorigenesis, enabling the use of HMTs or HDMs expression as potential biomarkers to 
discriminate benign (oncocytoma) from malignant (especially chRCC) RCTs. For that purpose, 
expression of 58 HMTs and 29 HDMs was screened in five oncocytomas and five chRCCs, as 
well as five renal normal tissue (RNTs) samples. Using strict criteria, three enzymes - SMYD2, 
SETD3 and NO66 – were selected for validation as they showed the highest fold-change. 
Because SMYD2 displayed the best biomarker performance, its role in renal tumorigenesis 
was further evaluated in renal cancer cell lines.  
The Taqman Array analysis included 87 enzymes involved in histone methylation, thus 
covering most of HMTs and HDMs thus far discovered. Careful and strict statistical analysis 
was performed in this first experiment, because the small number of samples analyzed is likely 
to introduce significant bias. Thus, a non-parametric (Mann-Whitney) test was used to select 
for significant changes in expression levels, resulting in a short list of 12 enzymes. Taking in 
consideration the main goal of this study, enzymes whose expression levels might discriminate 
RCT from normal tissues were then selected for validation in a larger series of primary tumors. 
Importantly, the three enzymes that surfaced in the array, meeting all the previous conditions - 
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SMYD2, SETD3 and NO66 – retained the altered pattern of expression initially uncovered in 
the array analysis. 
For most genes included in the expression array analysis, the observed alterations are 
in line with previous publications on their role in cancer. Thus, SETD2 has been proposed as a 
tumor suppressor in ccRCC [91] and it was mostly downregulated in RCT compared to RNTS. 
A similar trend was apparent for KDM5C, which was also reported to have a tumor suppressive 
effect [93]. Moreover, KDM6A was described as overexpressed in RCTs [95], and it was found 
to be second most upregulated enzyme in RCTs in our analysis. A divergent behavior was, 
however, observed for EZH2, which was reported to be upregulated in ccRCCs compared to 
adjacent normal tissues, suggesting an oncogenic role in RCC [95, 96], whereas we found 
EZH2 to be downregulated in RCTs. Notwithstanding this latter result, which might be due to 
the small number of cases used for array analysis and/or the use of adjacent morphologically 
normal renal tissue as control [which we have found to harbor epigenetic alterations [107]], the 
overall results of the array and the agreement found for the genes validated in the large series 
of primary tumors, are strong arguments in favor of the validity of our strategy for discovery of 
HDMs and HMTs as RCT biomarkers.  
 In the validation series, SMYD2, SETD3 and NO66 expression levels were significantly 
upregulated in RCTs, and chRCCs showed the higher expression compared to other 
histological subtypes. Apart from SETD3, whose expression levels were lower in pRCCs, all 
other enzymes displayed lower expression in ccRCC, although it was not significantly different 
from pRCCs. This finding might denote the common origin of ccRCC and pRCC, on the one 
hand, and of chRCC and oncocytoma, on the other, as previously suggested by other studies 
[13]. Indeed, differences in expression were mostly between tumors of different tubular origin, 
with the exception of SMYD2, which displayed statistically significant differences between 
chRCCs and oncocytomas. This is an important finding as these two histological subtypes may 
share morphological features that impair differential diagnosis, especially in small biopsies. 
Thus, we further tested which biomarker would provide the best performance and SMYD2 
expression levels were those that more accurately discriminated RCTs from RNT and also 
chRCCs from oncocytomas. However, if all subtypes of RCCs are included within the same 
group, SMYD2 is less accurate to discriminate benign from malignant RCTs, because the 
higher expression levels of chRCC are counterbalanced by the lowest levels found in ccRCC 
and pRCC. In this context, NO66 performed better, but its discriminative power is also modest. 
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Thus, the potential clinical usefulness of SMYD2 as a diagnostic biomarker would be mostly in 
cases in which differential diagnosis between oncocytoma and chRCC is challenging. 
The prognostic significance of altered SMYD2, SETD3 and NO66 mRNA expression 
levels was assessed through disease-specific and metastasis-free survival analysis. 
Interestingly, in univariate analysis low expression levels of all three genes associated with 
worse disease-specific survival. Similar analysis in other cancers were only reported for 
SMYD2 in esophageal squamous cell carcinoma, in which high levels of expression associated 
with worse outcome [108, 109]. Besides differences in tumor model, it should be emphasized 
that survival analysis results in our series are mostly influenced by pRCC and ccRCC 
(displaying low expression levels of the three genes), which are widely acknowledged as the 
most aggressive subtypes. This finding may also explain the lack of independent prognostic 
value in multivariate analysis. When variables were combined, however, SETD3 expression 
and Fuhrman grade reached statistically significance. Notwithstanding, these results should be 
analyzed with caution because only eight deaths due to cancer progression were found within 
the follow up period, and all occurred in patients with ccRCC or pRCC. Concerning metastasis-
free survival, the results parallel those of disease-specific survival and the same explanation 
holds true. Importantly, NO66 expression levels could independently predict metastasis free 
survival in this subset of patients, which might be a clinically relevant finding. 
To determine whether results observed at transcript level correlated with protein 
expression, immunohistochemistry was performed in formalin-fixed paraffin-embedded tissue 
samples from the same patient cohort. This was only accomplished for SETD3 and SMYD2, 
as no reliable antibody was available for NO66. We found that Score A, which combines 
immunostaining intensity and percentage of positive cells, statistically associated with transcript 
levels of SETD3 and SMYD2. Although these results suggest that SMYD2 and SETD3 IHC 
could be useful as an ancillary tool for histopathological evaluation, there is wide variation 
among the same tumor subtype and overlapping features between tumor subtypes, limiting its 
potential usefulness. 
Concerning the biological role of SMYD2, SETD3 and NO66 the former is a histone 
demethylase, whereas the latter two are histone methyltransferases [68]. To the best of our 
knowledge, only a few studies have been published concerning their role in tumorigenesis, but 
RCTs have not been investigated thus far. SMYD2 acts not only in histones, namely on lysine 
4 and lysine 36 of histone H3, but also in non-histone proteins such as P53, RB1, HSP90 and 
PARP1 [110-118]. It plays an important role in muscle function, mediating the methylation of 
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Hsp 90, which stabilizes the sarcomeric region [113]. Moreover, SMYD2 activity is critical at 
early stages of embryonic differentiation although its expression is mainly found in somatic cells 
compared to pluripotent [119]. In cancer, SMYD2 is overexpressed in esophageal squamous 
cell carcinoma, independently predicting poor survival [108], in bladder cancer [120] and 
leukemia [109]. SETD3, that also methylates lysine 4 and lysine 36 of histone H3, promotes 
the differentiation of muscle cells by inducing the expression of muscle differentiation markers 
such as myogenin [121]. In cancer, the only association was found in lymphomas, in which a 
SETD3 truncated form (not containing the SET domain sequence and thus lacking HMT 
activity) was found to be highly expressed, associating with oncogenic potential by inducing 
colony formation [122]. Finally, NO66, which specifically acts on lysines 4 and 36 of histone 
H3, is highly conserved in eukaryotes and it has mostly a nucleolar localization [123]. It plays 
a role in bone differentiation, as it directly interacts with Osterix (Osx), an osteoblast-specific 
transcription factor required for osteoblast differentiation and bone formation [124]. In fact, 
knockdown of NO66 in pre-osteoblasts induces the expression of Osx target genes, resulting 
in an acceleration of osteoblast differentiation and mineralization [124]. The chromatin of Osx-
target Bsp gene was associated with an increase of NO66 occupancy as well as low levels of 
histone methylation, suggesting that NO66 may induce the repression of chromatin through 
histone demethylation during osteoblast differentiation [125].  
Taking in consideration the aforementioned information about SMYD2, SETD3 and 
NO66, and that the first gene disclosed the best performance as RCT biomarker, we further 
explored the role of SMYD2 in renal tumorigenesis. Thus, phenotypic assays were carried out, 
using cell lines derived from ccRCC (786-O and Caki-1, derived from a primary tumor and from 
a metastasis, respectively), because no cell lines derived from chRCC or oncocytoma are 
available, and this must be taken in consideration in the analysis of the results. Intriguingly, 
SMYD2 silencing in 786-O cells resulted in increased proliferation and decrease of apoptosis, 
suggesting a putative tumor suppressor role for SMYD2. These results are in accordance with 
published data on the association of SMYD2 silencing with cell cycle arrest and apoptosis. 
Indeed, SMYD2 was reported to monomethylate RB1 at lysine 860, and this specific 
methylation was higher in quiescent cells compared with cells re-entering the cell cycle [117]. 
Moreover, a decrease in proliferation of embryonic fibroblast cells transfected with SMYD2 has 
been reported [112]. Conversely, Caki-1 cells, SMYD2 silencing decreased cell viability, 
proliferation and invasion capabilities, with a concomitant increase in apoptosis. Thus, in this 
cell line, SMYD2 seems to play an oncogenic role, which is in line with our results in primary 
tissue samples (in which SMYD2 was overexpressed in RCCs compared to RNTs). 
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Furthermore, the knockdown of SMYD2 led to decreased proliferation of KYSE150 cells, 
resulting in an accumulation of these cells in G0/G1 and a slight increase in sub-G1, with a 
concomitant increase of p21 [108]. Similar results have been also reported in SW780 and RT4 
cell lines, in which SMYD2 silencing led to reduced cell growth [120]. Furthermore, SMYD2 
induction resulted in an increase of cells in S phase with a concomitant decrease of the 
proportion of cells in G0/G1 [120]. In addition, a positive correlation between RB1 
phosphorylation status and SMYD2 expression has been found, suggesting that lysine 810 
methylation of RB1 by SMYD2 promotes cell cycle progression through an increase in RB1 
phosphorylation [120]. SMYD2 is also reported to methylate Hsp90, a protein chaperone which 
is important for protein folding [110, 113, 114, 126] and methylation of Hsp90, mediated by 
SMYD2, enhances dimerization of Hsp90AB1, which is more common in cancer cells, 
compared to normal cells [114]. Furthermore, SMYD2 downregulation results in decreased 
expression of ERBB2 and CDK4 oncogenes in RT4 and SW780 cell lines [114]. The anti-
apoptotic function of SMYD2 is also illustrated by the induction of apoptosis in cardiomyocites 
following SMYD2 knockdown [126]. Finally, the putative oncogenic role of SMYD2 is also 
supported by the repression of p53 function. In fact, SMYD2 downregulates p53 targets genes 
(namely p21), through methylation of lysine 370 of p53, and it also inhibits apoptosis in a p53-
dependent manner upon DNA damage [115]. Thus, the phenotypic effects observed in Caki-1 
cells are more likely to illustrate the role of SMYD2 in renal tumorigenesis, notwithstanding its 
metastatic origin. However, it should also be emphasized that Caki-1 cells displayed the highest 
expression levels among the tested cell lines, and thus are more close to the potential effect 
observed in primary chRCC, although the different genomic backgrounds precludes direct 
comparisons. 
Considering the published information regarding the effects of SMYD2 on proteins that 
participate in cell cycle control and apoptosis, we looked for alterations in TP53, p21, MDM2 
and RB1 in our cell model. Remarkably, downregulation of all genes was displayed in SMYD2-
silenced Caki-1 cells. These results seem counterintuitive for the tumor suppressors TP53, p21 
and RB1, but not for MDM2. Concerning MDM2, it is involved in regulation of p53 stability, 
repressing it when p53 expression levels rise [127]. Thus, in our cell model, as we have low 
expression levels of TP53, MDM2 will not be induced by it and, therefore, MDM2 expression 
levels would be also downregulated. Another way to interpret the results of selected gene 
expression in cell lines, is to look at them as a global effect. Because SMYD2 is responsible 
for the establishment of lysine 4 and lysine 36 methylation in H3, which are associated with 
active gene transcription, its inhibition might cause a global reduction of gene expression. 
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Moreover, transcript and respective protein levels might not correlate, as observed in KYSE220 
cell lines, in which upregulated SMYD2 mRNA expression levels are not paralled at protein 
level [108]. 
Finally, because SMYD2 gene displays a CpG island, DNA methylation might be a 
possible regulatory mechanism of SMYD2 expression. Considering the pattern of SMYD2 
expression in RNT and across RCT subtypes, differential methylation of SMYD2 promoter 
region might account for differential expression. Using three sets of primers, targeting different 
regions, either methylation was not found or it did not differ between RNT and RCT samples. 
Thus, we concluded that promoter methylation is not the most likely mechanism underlying 
differential expression in renal tissues and the role of other epigenetic (e.g., microRNAs 
deregulation) and/or genetic alterations require further investigatio
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Conclusions and Future Perspectives 
In this study we found that altered expression levels of enzymes involved in histone 
methylation are associated with renal tumorigenesis. Specifically, it was found that SMYD2 and 
SETD3, two histone methyltransferases of lysines 4 and 36 of H3, and NO66, a histone 
demethylase of the same lysines, were upregulated in RCTs compared to RNTs. Moreover, 
although SMYD2, SETD3 and NO66 expression levels were higher in chRCCs, they were also 
upregulated in oncocytomas compared to ccRCC and chRCC. SMYD2 expression levels 
discriminated RCT from RNT and chRCC from oncocytoma, whereas NO66 expression levels 
were able to distinguish malignant from benign RCTs. Survival analysis revealed that combined 
SETD3 expression levels and Fuhrman grade were independent prognostic factors for disease-
free survival, and NO66 expression predicted metastasis-free survival. Moreover, using 
immunohistochemistry, SMYD2 and SETD3 protein expression correlated with transcript levels 
and Score A might help in differential diagnosis of malignant and benign RCTs. In RCC cell 
lines, SMYD2 silencing resulted in divergent phenotypic effects, suggesting a tumor 
suppressive role in 786-O and an oncogenic function in Caki-1 cells. These results might be 
related with different (primary vs. metastatic) origin of cell lines, although Caki-1 seems to better 
mimic the expression findings in primary tumor tissues. Finally, the expression of several genes 
whose proteins are targeted by SMYD2 were shown to be deregulated in SMYD2-silenced 
cells. Overall, these results suggest that SMYD2 role may vary according to the cellular context. 
As future perspectives, we intend not only to consolidate some of the results already 
obtained but also to explore other mechanisms that might clarify the role of histone methylation 
enzymes in renal tumorigenesis, especially SMYD2. Firstly, we aim to validate other histone 
methylation enzymes, whose function is altered in RCT, such as SETD2 and KDM5C. The 
present study demonstrated that SMYD2, SETD3 and NO66 are involved in renal 
tumorigenesis. Because they all act on the same lysine residues, this is likely to be a relevant 
regulatory mechanism impaired in RCTs. Thus, it could be interesting to explore the role of 
other methylation enzymes that act in these same residues, such as KDM2B, which was 
overexpressed in RCTs in the array analysis. 
Considering the potential biomarker value of SMYD2, SETD3 and NO66, it would be 
important to evaluate its performance in clinical samples obtained through non- or minimally-
invasive techniques, such as urine or fine-needle aspiration biopsies. Furthermore, with the 
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purpose of understand the expression pattern of SMYD2 in metastasis, it would be relevant to 
evaluate its expression levels in tissue samples and compare with respective primary tumors. 
Moreover, the target genes assessed in in vitro model should be validated at protein level, to 
fully understand the impact of SMYD2 overexpression in pathways studies. Concerning the 
mechanisms underlying SMYD2 altered expression, miRNAs should be explored, as these are 
also frequently and differentially altered in RCTs, as recently shown in a study from our 
research team [128].  
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Supplementary Table 1 – Histone methyltransferases and histone demethylases analysed in this study and their 
respectively lozalization on chromossomes. 
Gene 
Symbol 
Localization Oficial Name 
ASH1L 1q22 ash1 (absent, small, or homeotic)-like (Drosophila) 
C14orf169 14q24.3 Chromosome 14 open reading frame 169 
CARM1 19p13.2 Coactivator-associated arginine methyltransferase 1 
DOT1L 19p13.3 DOT1-like histone H3K79 methyltransferase 
EHMT1 9q34.3 Euchromatic histone-lysine N-methyltransferase 1 
EHMT2 6p21.31 Euchromatic histone-lysine N-methyltransferase 2 
EZH1 17q21.1-q21.3 Enhancer of zeste 1 polycomb repressive complex 2 
subunit 
EZH2 7q35-q36 Enhancer of zeste 2 polycomb repressive complex 2 
subunit 
JARID2 6p24-p23 Jumonji, AT rich interactive domain 2 
JHDM1D 7q34 Lysine (K)-specific demethylase 7A 
JMJD1C 10q21.3 Jumonji domain containing 1C 
JMJD6 17q25 Jumonji domain containing 6 
KDM1A 1p36.12 Lysine (K)-specific demethylase 1A 
KDM1B 6p22.3 Lysine (K)-specific demethylase 1B 
KDM2A 11q13.2 Lysine (K)-specific demethylase 2A 
KDM2B 12q24.31 Lysine (K)-specific demethylase 2B 
KDM3A 2p11.2 Lysine (K)-specific demethylase 3A 
KDM3B 5q31 Lysine (K)-specific demethylase 3B 
KDM4A 1p34.1 Lysine (K)-specific demethylase 4A 
KDM4B 19p13.3 Lysine (K)-specific demethylase 4B 
KDM4C 9p24.1 Lysine (K)-specific demethylase 4C 
KDM4D 11q21 Lysine (K)-specific demethylase 4D 
KDM4E 11q21 Lysine (K)-specific demethylase 4E 
KDM5A 12p11 Lysine (K)-specific demethylase 5A 
KDM5B 1q32.1 Lysine (K)-specific demethylase 5B 
KDM5C Xp11.22-p11.21 Lysine (K)-specific demethylase 5C 
KDM5D Yq11 Lysine (K)-specific demethylase 5D 
KDM6A Xp11.2 Lysine (K)-specific demethylase 6A 
KDM6B 17p13.1 Lysine (K)-specific demethylase 6B 
KDM8 16p12.1 Lysine (K)-specific demethylase 8 
MECOM 3q26.2 MDS1 and EVI1 complex locus 
MINA 3q11.2 MYC induced nuclear antigen 
MLL 11q23 Lysine (K)-specific methyltransferase 2A 
MLL2 12q13.12 Lysine (K)-specific methyltransferase 2D 
MLL3 7q36.1 Lysine (K)-specific methyltransferase 2C 
MLL4 19q13.1 Lysine (K)-specific methyltransferase 2B 
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IV 
MLL5 7q22.1 Lysine (K)-specific methyltransferase 2E 
NSD1 5q35 Nuclear receptor binding SET domain protein 1 
PADI4 1p36.13 Peptidyl arginine deiminase, type IV 
PHF2 9q22.31 PHD finger protein 2 
PHF8 Xp11.22 PHD finger protein 8 
PRDM1 6q21 PR domain containing 1, with ZNF domain 
PRDM10 11q25 PR domain containing 10 
PRDM11 11p11 PR domain containing 11 
PRDM12 9q33-q34 PR domain containing 12 
PRDM13 6q16.2 PR domain containing 13 
PRDM14 8q13.3 PR domain containing 14 
PRDM15 21q22.3 PR domain containing 15 
PRDM16 1p36.23-p33 PR domain containing 16 
PRDM2 1p36.21 PR domain containing 2, with ZNF domain 
PRDM4 12q23-q24.1 PR domain containing 4 
PRDM5 4q25-q26 PR domain containing 5 
PRDM6 5q23.2 PR domain containing 6 
PRDM7 16q24.3 PR domain containing 7 
PRDM8 4q21 PR domain containing 8 
PRDM9 5p14 PR domain containing 9 
PRMT1 19q13.3 Protein arginine methyltransferase 1 
PRMT2 21q22.3 Protein arginine methyltransferase 2 
PRMT3 11p15.1 Protein arginine methyltransferase 3 
PRMT5 14q11.2 Protein arginine methyltransferase 5 
PRMT6 1p13.3 Protein arginine methyltransferase 6 
PRMT7 16q22.1 Protein arginine methyltransferase 7 
PRMT8 12p13.3 Protein arginine methyltransferase 8 
SETD1A 16p11.2 SET domain containing 1A 
SETD1B 12q24.31 SET domain containing 1B 
SETD2 3p21.31 SET domain containing 2 
SETD3 14q32.2 SET domain containing 3 
SETD4 21q22.13 SET domain containing 4 
SETD5 3p25.3 SET domain containing 5 
SETD6 16q21 SET domain containing 6 
SETD7 4q28 SET domain containing 7 
SETD8 12q24.31 SET domain containing 8 
SETDB1 1q21 SET domain, bifurcated 1 
SETDB2 13q14 SET domain, bifurcated 2 
SETMAR 3p26.1 SET domain and mariner transposase fusion gene 
SMYD1 2p11.2 SET and MYND domain containing 1 
SMYD2 1q32.3 SET and MYND domain containing 2 
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V 
SMYD3 1q44 SET and MYND domain containing 3 
SMYD4 17p13.3 SET and MYND domain containing 4 
SMYD5 2p13.2 SET and MYND domain containing 5 
SUV39H1 Xp11.23 suppressor of variegation 3-9 homolog 1 
SUV39H2 10p13 suppressor of variegation 3-9 homolog 2 
SUV420H1 11q13.2 suppressor of variegation 4-20 homolog 1 
SUV420H2 19q13.42 suppressor of variegation 4-20 homolog 2 
UTY Yq11 Ubiquitously transcribed tetratricopeptide repeat 
containing, Y-linked 
WHSC1 4p16.3 Wolf-Hirschhorn syndrome candidate 1 
WHSC1L1 8p11.2 Wolf-Hirschhorn syndrome candidate 1-like 1 
 
 
 
Supplementary Figure 1 –Kaplan-Meier estimated disease-specific survival curves of 
62 RCC patients according to pathological stage (A), Fuhrman Grade (B) and 
Histological Subtype (C). 
 
 
